<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"
  dtd-version="3.0" article-type="research-article" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rev Saude Publica</journal-id>
      <journal-title-group>
        <journal-title>Revista de Saúde Pública</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Rev. Saúde Pública</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0034-8910</issn>
      <issn pub-type="epub">1518-8787</issn>
      <publisher>
        <publisher-name>Faculdade de Saúde Pública da Universidade de São Paulo</publisher-name>
        <publisher-loc>São Paulo</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">S0034-8910.2013047004529</article-id>
      <article-id pub-id-type="doi">10.1590/S0034-8910.2013047004529</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Prática de Saúde Pública</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="pt">Antivirais incorporados no Brasil para hepatite B crônica:
          análise de custo-efetividade</article-title>
        <trans-title-group xml:lang="es">
          <trans-title>Antivirales incorporados en Brasil para hepatitis B crónica: análisis de
            costo-efectividad</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Oliveira</surname>
            <given-names>Gustavo Laine Araújo de</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">I</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Almeida</surname>
            <given-names>Alessandra Maciel</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">II</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silva</surname>
            <given-names>Anderson Lourenço da</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">III</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brandão</surname>
            <given-names>Cristina Mariano Ruas</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">IV</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Andrade</surname>
            <given-names>Eli Iola Gurgel</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">V</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cherchiglia</surname>
            <given-names>Mariângela Leal</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">V</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Acurcio</surname>
            <given-names>Francisco de Assis</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">IV</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>I</label>
        <institution content-type="orgdiv1">Faculdade de Farmácia</institution>
        <institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
        <addr-line>
          <named-content content-type="city">Belo Horizonte</named-content>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country>Brasil</country> Programa de Pós-Graduação em Medicamentos e Assistência
        Farmacêutica. Faculdade de Farmácia. Universidade Federal de Minas Gerais. Belo Horizonte,
        MG, Brasil</aff>
      <aff id="aff2">
        <label>II</label>
        <institution content-type="orgdiv1">Departamento de Medicina Preventiva</institution>
        <institution content-type="orgname">Faculdade de Ciências Médicas de Minas
          Gerais</institution>
        <addr-line>
          <named-content content-type="city">Belo Horizonte</named-content>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country>Brasil</country> Departamento de Medicina Preventiva. Faculdade de Ciências
        Médicas de Minas Gerais. Belo Horizonte, MG, Brasil</aff>
      <aff id="aff3">
        <label>III</label>
        <institution content-type="orgdiv1">Superintendente de Assistência Farmacêutica e Insumos
          Estratégicos</institution>
        <institution content-type="orgname">Secretaria de Estado de Saúde</institution>
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <country>Brasil</country> Superintendente de Assistência Farmacêutica e Insumos Estratégicos
        . Secretaria de Estado de Saúde. Rio de Janeiro, RJ, Brasil</aff>
      <aff id="aff4">
        <label>IV</label>
        <institution content-type="orgdiv2">Departamento de Farmácia Social</institution>
        <institution content-type="orgdiv1">Faculdade de Farmácia</institution>
        <institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
        <addr-line>
          <named-content content-type="city">Belo Horizonte</named-content>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country>Brasil</country> Departamento de Farmácia Social. Faculdade de Farmácia.
        Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil</aff>
      <aff id="aff5">
        <label>V</label>
        <institution content-type="orgdiv2">Departamento de Medicina Preventiva e
          Social</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina</institution>
        <institution content-type="orgname">Universidade Federal de Minas Gerais</institution>
        <addr-line>
          <named-content content-type="city">Belo Horizonte</named-content>
          <named-content content-type="state">MG</named-content>
        </addr-line>
        <country>Brasil</country> Departamento de Medicina Preventiva e Social . Faculdade de
        Medicina. Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil</aff>
      <author-notes>
        <corresp>
          <bold>Correspondência | Correspondence</bold> : Gustavo Laine Araújo de Oliveira.
          Faculdade de Farmácia. Universidade Federal de Minas Gerais. Av. Presidente Antônio
          Carlos, 6627. Sala 1040B2 Pampulha. 31270-901 Belo Horizonte, MG, Brasil. E-mail:
          gustavolaine@gmail.coml</corresp>
        <fn fn-type="financial-disclosure">
          <p>Pesquisa realizada com apoio financeiro da Coordenação de Aperfeiçoamento de Pessoal de
            Nível Superior (CAPES), bolsa de mestrado outorgada a Oliveira G.L.A, em conjunto com o
            Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (Edital
            MCT/CNPq/MS-SCTIE-DECIT/CT – Saúde nº 033/2007; CNPq – Processo nº 551412/2007-0), e da
            Fundação de Amparo à Pesquisa do Estado de Minas Gerais (Fapemig).</p>
        </fn>
        <fn fn-type="conflict">
          <p>Os autores declaram não haver conflito de interesses.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>08</month>
        <year>2013</year>
      </pub-date>
      <volume>47</volume>
      <issue>4</issue>
      <fpage>769</fpage>
      <lpage>780</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>8</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>4</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access"
          xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
            Commons Attribution Non-Commercial License, which permits unrestricted non-commercial
            use, distribution, and reproduction in any medium, provided the original work is
            properly cited.</license-p>
        </license>
      </permissions>
      <abstract xml:lang="pt">
        <sec>
          <title>OBJETIVO</title>
          <p> Avaliar o custo-efetividade de diferentes tratamentos medicamentosos para hepatite B
            crônica entre pacientes adultos.</p>
        </sec>
        <sec>
          <title>MÉTODOS</title>
          <p> Utilizando modelo de Markov, construiu-se coorte hipotética de 40 anos para pacientes
            HBeAg-positivo ou HBeAg-negativo. Foram comparados os usos de adefovir, entecavir,
            tenofovir e lamivudina (com terapia de resgate em caso de resistência viral) para
            tratamento de pacientes adultos com hepatite B crônica, virgens de tratamento, com
            elevados níveis de alanina aminotransferase, sem evidência de cirrose e sem coinfecção
            por HIV. Valores para custo e efeito foram obtidos da literatura. A medida do efeito foi
            expressa em anos de vida ganhos (AVG). Taxa de desconto de 5% foi aplicada. Análise de
            sensibilidade univariada foi conduzida para avaliar incertezas do modelo.</p>
        </sec>
        <sec>
          <title>RESULTADOS</title>
          <p> O tratamento inicial com entecavir ou tenofovir apresentou melhores resultados
            clínicos. As menores razões custo-efetividade foram de entecavir para pacientes
            HBeAg-positivo (R$ 4.010,84/AVG) e lamivudina para pacientes HBeAg-negativo (R$
            6.205,08/AVG). Para pacientes HBeAg-negativo, a razão custo-efetividade incremental de
            entecavir (R$ 14.101,05/AVG) está abaixo do limiar recomendado pela Organização Mundial
            da Saúde. Análise de sensibilidade mostrou que variação nos custos dos medicamentos pode
            tornar tenofovir alternativa custo-efetiva tanto para pacientes HBeAg-positivo quanto
            para HBeAg-negativo.</p>
        </sec>
        <sec>
          <title>CONCLUSÕES</title>
          <p> Entecavir é alternativa recomendada para iniciar o tratamento de pacientes com
            hepatite B crônica no Brasil. Contudo, se houver redução no custo de tenofovir, esta
            pode se tornar alternativa mais custo-efetiva.</p>
        </sec>
      </abstract>
      <trans-abstract xml:lang="es">
        <sec>
          <title>OBJETIVO</title>
          <p>Evaluar el costo-efectividad de diferentes tratamientos medicamentosos para hepatitis B
            crónica entre pacientes adultos.</p>
        </sec>
        <sec>
          <title>MÉTODOS</title>
          <p>Utilizando el modelo de Markov, se construyó cohorte hipotética de 40 años para
            pacientes HBeAg-positivo o HBeAg-negativo. Se compararon los usos de adefovir,
            entecavir, tenofovir y lamivudina (con terapia de rescate en caso de resistencia viral)
            para tratamiento de pacientes adultos con hepatitis B crónica, vírgenes de tratamiento,
            con elevados niveles de alanina aminotransferasa, sin evidencia de cirrosis y sin
            coinfección por VIH. Valores para costo y efecto fueron obtenidos de la literatura y
            efecto en años de vida ganados (AVG). Tasa de descuento de 5% fue aplicada. Análisis de
            sensibilidad univariado fue conducido para evaluar incertidumbres del modelo.</p>
        </sec>
        <sec>
          <title>RESULTADOS</title>
          <p>El tratamiento inicial con entecavir o tenofovir presentó mejores resultados clínicos.
            Los menores cocientes costo-efectividad fueron de entecavir para pacientes
            HBeAg-positivo (R.010,84/AVG) y lamivudina para pacientes HBeAg-negativo
            (R.205,08/AVG).Para pacientes HBeAg-negativo, el cociente costo-efectividad incrementado
            de entecavir (R.101,05/AVG) está por debajo del límite recomendado por la Organización
            Mundial de la Salud. El análisis de sensibilidad mostró que la variación en los costos
            de los medicamentos puede tornar tenofovir una alternativa costo-efectiva tanto para
            pacientes HBeAg-positivo como para los HBeAg-negativo.</p>
        </sec>
        <sec>
          <title>CONCLUSIONES</title>
          <p>Entecavir es una alternativa recomendada para iniciar el tratamiento de pacientes con
            hepatitis B crónica en Brasil. Sin embargo, al haber reducción en el costo de tenofovir,
            éste puede convertirse en una alternativa más costo-efectiva.</p>
        </sec>
      </trans-abstract>
      <kwd-group xml:lang="pt">
        <kwd>Hepatite B Crônica, quimioterapia</kwd>
        <kwd>Antivirais, provisão &amp; distribuição</kwd>
        <kwd>Avaliação de Custo-Efetividade</kwd>
        <kwd>Sistema Único de Saúde, economia</kwd>
      </kwd-group>
      <kwd-group xml:lang="es">
        <kwd>Hepatitis B Crónica, quimioterapia</kwd>
        <kwd>Antivirales, provisión &amp; distribución</kwd>
        <kwd>Avaliación de Costo-Efectividad</kwd>
        <kwd>Sistema Único de Salud, economía</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>Conselho Nacional de Desenvolvimento Científico e
            Tecnológico</funding-source>
          <award-id>551412/2007-0</award-id>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="2"/>
        <table-count count="8"/>
        <ref-count count="31"/>
        <page-count count="12"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUÇÃO</title>
      <p>A hepatite B crônica (HBC) é uma doença de alta prevalência, sendo estimados 350 milhões de
        casos em todo o mundo. <xref ref-type="bibr" rid="B13">
          <sup>13</sup>
        </xref> De acordo com dados do Sistema de Informação de Agravos de Notificação (SINAN) para
        o período entre 1999 e 2010, foram confirmados 104.454 casos da doença no Brasil. Somente em
        2009 foram 14.468 casos confirmados, proporcionando taxa de detecção de 7,6 a cada 100.000
        habitantes. <xref ref-type="fn" rid="fn1">
          <sup>a</sup>
        </xref> Pacientes com HBC podem desenvolver doença hepática progressiva, que pode resultar
        em cirrose e carcinoma hepatocelular. Esses estágios da doença estão associados a risco
        aumentado de morbidade e mortalidade, além de implicarem consideráveis gastos em saúde.
          <xref ref-type="bibr" rid="B21">
          <sup>21</sup>
        </xref>
      </p>
      <p>A HBC é causada pelo vírus da hepatite B (VHB) e o diagnóstico é confirmado se o paciente
        apresentar antígeno de superfície da hepatite B viral (HBsAg) por pelo menos seis meses, bem
        como o aumento das enzimas hepáticas e achados histológicos. Esses pacientes podem ser
        subdivididos, com base na presença do antígeno “e” da hepatite B (HBeAg) no soro, em
        HBeAg-positivo ou HBeAg-negativo. Esses grupos diferem em relação à história natural e
        resposta à terapia antiviral, sendo os pacientes HBeAg-negativo frequentemente associados a
        piores prognóstico e resposta ao tratamento. <xref ref-type="bibr" rid="B25">
          <sup>25</sup>
        </xref> O tratamento da HBC objetiva atingir supressão sustentada da replicação do VHB,
        remissão de doença hepática, evitar o desenvolvimento de cirrose, insuficiência hepática ou
        carcinoma hepatocelular. Em pacientes HBeAg-positivo, a soroconversão durável de HBeAg para
        anti-HBe é um importante marcador, associado a melhores prognósticos. <xref ref-type="bibr"
          rid="B11">
          <sup>11</sup>
        </xref>
      </p>
      <p>No Brasil, até 2009, interferon e lamivudina eram os únicos tratamentos padronizados para
        HBC no Sistema Único de Saúde (SUS). Os medicamentos adefovir dipivoxil, entecavir,
        interferon peguilado e tenofovir foram, então, incorporados às diretrizes terapêuticas dessa
        doença. Estabeleceram-se como primeira escolha de tratamento o interferon para os pacientes
        HBeAg-positivo e o tenofovir para os HBeAg-negativo. <xref ref-type="fn" rid="fn2">
          <sup>b</sup>
        </xref> Esses seis medicamentos fazem parte do Componente Especializado da Assistência
        Farmacêutica (CEAF) e são disponibilizados aos cidadãos por meio da Política Nacional de
        Assistência Farmacêutica, do Ministério da Saúde. <xref ref-type="fn" rid="fn3">
          <sup>c</sup>
        </xref>
      </p>
      <p>Os gastos com financiamento de medicamentos do CEAF têm demonstrado tendência ininterrupta
        de crescimento no SUS, variando de R$ 685 milhões em 2000 (R$ 4,01 <italic>per
          capita</italic> ) para R$ 1,41 bilhões em 2007 (R$ 7,40 <italic>per capita</italic> ).
          <xref ref-type="bibr" rid="B2">
          <sup>2</sup>
        </xref>
        <sup>,</sup>
        <xref ref-type="fn" rid="fn4">
          <sup>d</sup>
        </xref> Essa situação gera a necessidade de otimização dos recursos financeiros destinados à
        saúde.</p>
      <p>São escassas as evidências enfocando a utilização de tenofovir para o contexto brasileiro.
        Para reiterar ou rejeitar as opções estabelecidas nas diretrizes terapêuticas, torna-se
        importante a realização de estudos para melhor compreensão do impacto econômico e dos
        resultados obtidos para a saúde pública.</p>
      <p>O presente estudo teve por objetivo avaliar o custo-efetividade de diferentes tratamentos
        medicamentosos para hepatite B crônica entre pacientes adultos.</p>
    </sec>
    <sec sec-type="methods">
      <title>MÉTODOS</title>
      <p>Por meio de modelo de Markov, <xref ref-type="bibr" rid="B29">
          <sup>29</sup>
        </xref> utilizando o programa <italic>Tree Age Pro Suite 2009</italic> ( <italic>Tree Age
          Software, Inc</italic> ), constituiu-se uma coorte hipotética para pacientes HBeAg
        positivo e outra para pacientes HBeAg negativo. Ambas compreenderam quatro grupos, cada um
        relativo ao uso de adefovir dipivoxil (ADV), entecavir (ETV), lamivudina (LAM) ou tenofovir
        (TDF). Foram considerados tratamentos de pacientes adultos com hepatite B crônica, virgens
        de tratamento, com elevados níveis de alanina aminotransferase, sem evidência de cirrose e
        sem coinfecção por HIV. O modelo compreendeu horizonte temporal de 40 anos. Como medida de
        efetividade, consideraram-se os anos de vida ganhos (AVG) por paciente tratado. Somente
        custos diretos foram considerados, sendo estes expressos em moeda brasileira (R$). A
        perspectiva de análise adotada foi a do SUS, ou seja, a avaliação dos resultados de
        custo-efetividade dos tratamentos foi feita considerando os custos diretos do
        tratamento.</p>
      <p>O modelo foi composto por sete estados de transição, mutuamente exclusivos, que
        corresponderam aos seis estágios possíveis decorrentes da doença (HBC sem complicações,
        eficácia do tratamento, cirrose compensada, cirrose descompensada, carcinoma hepatocelular e
        óbito) e a resistência do VHB ao respectivo medicamento. Para pacientes HBeAg positivo,
        considerou-se a soroconversão HBeAg/Anti-HBe como desfecho de eficácia. Para pacientes HBeAg
        negativo, o desfecho analisado foi a indetecção de DNA do VHB no soro (&lt; 400
        cópias/mL).</p>
      <p>Cada ciclo do modelo correspondeu a um ano de tratamento. No primeiro ciclo, a população
        foi composta por indivíduos com HBC, sem complicações da doença ou resistência ao
        medicamento. A transição do primeiro para o segundo ciclo, e sucessivamente, ocorreu de
        acordo com as probabilidades de transição entre cada estado. Para pacientes que apresentaram
        resistência viral ao tratamento inicial, foi modelado tratamento de resgate representando a
        inserção de outro análogo de nucleos(t)ídeo à terapia. As probabilidades de transição foram
        compostas por dados de progressão da doença ( <xref ref-type="table" rid="t01">Tabela
          1</xref> ) e de eficácia dos medicamentos ( <xref ref-type="table" rid="t02">Tabela
          2</xref> ) obtidos, respectivamente, de estudos clínicos aleatorizados e de estudos sobre
        a história natural da HBC.</p>
      <p>
        <table-wrap id="t01">
          <label>Tabela 1</label>
          <caption>
            <title>Taxas anuais de progressão da doença.</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="25%">
              <col width="50%"/>
              <col/>
              <col/>
            </colgroup>
            <tbody>
              <tr>
                <td>Taxa de progressão anual</td>
                <td align="center">Taxa anual (%)</td>
                <td align="center">Nº referência</td>
              </tr>
              <tr>
                <td colspan="3" style="border-bottom: thin solid; border-color: #000000"/>
              </tr>
              <tr>
                <td>HBC para CC (HBeAg-positivo)</td>
                <td align="center">6,00</td>
                <td align="center">12, 19, 20</td>
              </tr>
              <tr>
                <td>HBC para CC (HBeAg-negativo)</td>
                <td align="center">9,00</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td>Soroconversão HBeAg-para CC</td>
                <td align="center">1,00</td>
                <td align="center">9</td>
              </tr>
              <tr>
                <td>Resposta combinada para CC</td>
                <td align="center">1,30</td>
                <td align="center">19</td>
              </tr>
              <tr>
                <td>CC para CD</td>
                <td align="center">5,00</td>
                <td align="center">9</td>
              </tr>
              <tr>
                <td>HCB para CHC</td>
                <td align="center">0,50</td>
                <td align="center">10, 31</td>
              </tr>
              <tr>
                <td>CC para CHC</td>
                <td align="center">2,50</td>
                <td align="center">8, 9, 10, 31</td>
              </tr>
              <tr>
                <td>CD para CHC</td>
                <td align="center">2,50</td>
                <td align="center">9</td>
              </tr>
              <tr>
                <td>HCB para óbito</td>
                <td align="center">0,35</td>
                <td align="center">30</td>
              </tr>
              <tr>
                <td>CC para óbito</td>
                <td align="center">5,00</td>
                <td align="center">17, 28</td>
              </tr>
              <tr>
                <td>CD para óbito</td>
                <td align="center">39,00</td>
                <td align="center">9, 31</td>
              </tr>
              <tr>
                <td>CHC para óbito (HBeAg-positivo)</td>
                <td align="center">56,00</td>
                <td align="center">31</td>
              </tr>
              <tr>
                <td>CHC para óbito (HBeAg-negativo)</td>
                <td align="center">37,20</td>
                <td align="center">27</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>CC: cirrose compensada; CD: cirrose descompensada; CHC: carcinoma hepatocelular; HBC:
              hepatite B crônica</p>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>
        <table-wrap id="t02">
          <label>Tabela 2</label>
          <caption>
            <title>Probabilidades anuais relacionadas aos tratamentos usados no modelo.</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="17%">
              <col width="30%"/>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <tbody>
              <tr>
                <td rowspan="3">Estratégia de tratamento</td>
                <td colspan="2" align="center">HBeAg-positivo</td>
                <td colspan="2" align="center">HBeAg-negativo</td>
              </tr>
              <tr>
                <td colspan="4" style="border-bottom: thin solid; border-color: #000000"/>
              </tr>
              <tr>
                <td align="center">Probabilidade (%)</td>
                <td align="center">Nº referência</td>
                <td align="center">Probabilidade (%)</td>
                <td align="center">Nº referência</td>
              </tr>
              <tr>
                <td colspan="5" style="border-bottom: thin solid; border-color: #000000"/>
              </tr>
              <tr>
                <td>Adefovir</td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
              </tr>
              <tr>
                <td> Resposta, ano 1</td>
                <td align="center">12</td>
                <td align="center">22</td>
                <td align="center">51</td>
                <td align="center">14</td>
              </tr>
              <tr>
                <td> Resposta, ano 2-4</td>
                <td align="center">13</td>
                <td align="center">Assumido igual para todos</td>
                <td align="center">15</td>
                <td align="center">14</td>
              </tr>
              <tr>
                <td> Resistência, ano 1</td>
                <td align="center">0</td>
                <td align="center">11</td>
                <td align="center">0</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 2</td>
                <td align="center">3</td>
                <td align="center">11</td>
                <td align="center">3</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 3</td>
                <td align="center">11</td>
                <td align="center">11</td>
                <td align="center">11</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 4</td>
                <td align="center">18</td>
                <td align="center">11</td>
                <td align="center">18</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 5</td>
                <td align="center">29</td>
                <td align="center">11</td>
                <td align="center">29</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td>Entecavir</td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
              </tr>
              <tr>
                <td> Resposta, ano 1</td>
                <td align="center">21</td>
                <td align="center">4</td>
                <td align="center">90</td>
                <td align="center">16</td>
              </tr>
              <tr>
                <td> Resposta, ano 2-4</td>
                <td align="center">13</td>
                <td align="center">Assumido igual para todos</td>
                <td align="center">42</td>
                <td align="center">16</td>
              </tr>
              <tr>
                <td> Resistência, ano 1</td>
                <td align="center">0,2</td>
                <td align="center">11</td>
                <td align="center">0,2</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 2</td>
                <td align="center">0,5</td>
                <td align="center">11</td>
                <td align="center">0,5</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 3</td>
                <td align="center">1,2</td>
                <td align="center">11</td>
                <td align="center">1,2</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 4</td>
                <td align="center">1,2</td>
                <td align="center">11</td>
                <td align="center">1,2</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 5</td>
                <td align="center">1,2</td>
                <td align="center">11</td>
                <td align="center">1,2</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td>Lamivudina</td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
              </tr>
              <tr>
                <td> Resposta, ano 1</td>
                <td align="center">19</td>
                <td align="center">18</td>
                <td align="center">73</td>
                <td align="center">16</td>
              </tr>
              <tr>
                <td> Resposta, ano 2-4</td>
                <td align="center">13</td>
                <td align="center">Assumido igual para todos</td>
                <td align="center">29</td>
                <td align="center">16</td>
              </tr>
              <tr>
                <td> Resistência, ano 1</td>
                <td align="center">24</td>
                <td align="center">11</td>
                <td align="center">24</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 2</td>
                <td align="center">38</td>
                <td align="center">11</td>
                <td align="center">38</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 3</td>
                <td align="center">49</td>
                <td align="center">11</td>
                <td align="center">49</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 4</td>
                <td align="center">67</td>
                <td align="center">11</td>
                <td align="center">67</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 5</td>
                <td align="center">70</td>
                <td align="center">11</td>
                <td align="center">70</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td>Tenofovir</td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
              </tr>
              <tr>
                <td> Resposta, ano 1</td>
                <td align="center">21</td>
                <td align="center">24</td>
                <td align="center">93</td>
                <td align="center">24</td>
              </tr>
              <tr>
                <td> Resposta, ano 2-4</td>
                <td align="center">13</td>
                <td align="center">Assumido igual para todos</td>
                <td align="center">42</td>
                <td align="center">Assumido igual ao entecavir</td>
              </tr>
              <tr>
                <td> Resistência, ano 1</td>
                <td align="center">0</td>
                <td align="center">11</td>
                <td align="center">0</td>
                <td align="center">11</td>
              </tr>
              <tr>
                <td> Resistência, ano 2</td>
                <td align="center">0</td>
                <td align="center">Assumido igual ao ano 1</td>
                <td align="center">0</td>
                <td align="center">Assumido igual ao ano 1</td>
              </tr>
              <tr>
                <td> Resistência, ano 3</td>
                <td align="center">0</td>
                <td align="center">Assumido igual ao ano 1</td>
                <td align="center">0</td>
                <td align="center">Assumido igual ao ano1</td>
              </tr>
              <tr>
                <td> Resistência, ano 4</td>
                <td align="center">0</td>
                <td align="center">Assumido igual ao ano 1</td>
                <td align="center">0</td>
                <td align="center">Assumido igual ao ano 1</td>
              </tr>
              <tr>
                <td> Resistência, ano 5</td>
                <td align="center">0</td>
                <td align="center">Assumido igual ao ano 1</td>
                <td align="center">0</td>
                <td align="center">Assumido igual ao ano 1</td>
              </tr>
              <tr>
                <td>Durabilidade da resposta</td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
              </tr>
              <tr>
                <td> Tratamento inicial</td>
                <td align="center">80</td>
                <td align="center">Assumido igual para todos</td>
                <td align="center">10</td>
                <td align="center">15, 16, 23</td>
              </tr>
              <tr>
                <td>Tratamento resgate</td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
              </tr>
              <tr>
                <td> Resposta, ano 2</td>
                <td align="center">8</td>
                <td align="center">26</td>
                <td align="center">52</td>
                <td align="center">5</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </p>
      <p>A literatura sobre a história natural da doença, eficácia e efetividade de seus tratamentos
        é escassa. Os medicamentos estudados nesta avaliação econômica são de recente aprovação
        pelas agências reguladoras. Dessa forma, a seleção dos estudos foi feita arbitrariamente,
        com base em avaliações econômicas, protocolos clínicos (como EASL e AASLD) e ensaios
        clínicos publicados.</p>
      <p>A modelagem foi realizada considerando algumas premissas, a saber: pacientes sem resposta
        ao tratamento continuaram recebendo a medicação por todo o período da coorte caso não
        desenvolvessem resistência; tratamento de resgate foi inserido aos pacientes que
        desenvolveram resistência aos tratamentos iniciais; não se considerou surgimento de
        resistência ao tratamento de resgate; pacientes em diferentes estágios da doença seguiram a
        história natural da HBC.</p>
      <p>Os valores monetários das terapias medicamentosas consideradas no estudo foram os
        determinados pela Câmara de Regulação do Mercado de Medicamentos para o ano 2011,
        considerando os preços de fábrica sem ICMS, já descontado o Coeficiente de Adequação de
        Preços de 24,38%. <xref ref-type="fn" rid="fn5">
          <sup>e</sup>
        </xref>
      </p>
      <p>Os gastos anuais por paciente, de acordo com os estágios da doença, foram obtidos de um
        estudo que avaliou os custos diretos da HBC em 2005, no Brasil. <xref ref-type="bibr"
          rid="B3">
          <sup>3</sup>
        </xref> Os valores foram corrigidos pelo Índice Nacional de Preços ao Consumidor Amplo
        (IPCA) para o ano de 2011. Os custos incluíram honorários médicos, exames laboratoriais,
        procedimentos diagnósticos e terapêuticos, internações hospitalares e gastos com
        medicamentos não antivirais. Os valores estimados foram extraídos predominantemente a partir
        de tabelas de pagamento do SUS.</p>
      <p>Em avaliações econômicas de tecnologias em saúde, é recomendado o uso de taxa de desconto
        no custo e na efetividade. Considerando que frequentemente existe diferença no tempo entre o
        investimento de recursos do serviço de saúde e o benefício em saúde a ele associado, foi
        utilizada a taxa arbitrária de 5% para custos e efeitos, recomendada pelo Ministério da
        Saúde, quando o universo temporal de análise era superior a um ano. <xref ref-type="fn"
          rid="fn6">
          <sup>f</sup>
        </xref> Também foram realizadas análises considerando descontos de 0% e 10% para custos e
        efeitos, de forma a avaliar em que extensão a seleção arbitrária da taxa afetou a conclusão
        do estudo. <xref ref-type="fn" rid="fn7">
          <sup>g</sup>
        </xref>
      </p>
      <p>Ao final da coorte hipotética, para cada grupo foram obtidos dados sobre a expectativa
        média de vida dos pacientes e a proporção dos pacientes em cada estágio da doença.
        Calcularam-se as médias de custo e efetividade, de acordo com a intervenção. Para cada
        intervenção, foi calculada a razão custo-efetividade (RCE), que determina o valor médio
        gasto para cada AVG. Para a comparação entre as alternativas, calculou-se a razão
        custo-efetividade incremental (RCEI), que é a razão entre as diferenças de custo médio de
        duas alternativas terapêuticas e as respectivas diferenças de AVG. A RCEI representa, em
        relação a uma alternativa de RCE menor, o incremento de recursos financeiros necessário para
        a obtenção de um AVG adicional. Uma intervenção foi considerada custo-efetiva se o valor de
        RCEI foi inferior a R$ 57.048,00, <xref ref-type="fn" rid="fn4">
          <sup>d</sup>
        </xref> equivalente ao triplo do Produto Interno Bruto (PIB) <italic>per capita</italic>
        brasileiro em 2011, adaptado conforme orientação da Organização Mundial da Saúde (OMS).
          <xref ref-type="fn" rid="fn8">
          <sup>h</sup>
        </xref>
      </p>
      <p>Conduziu-se análise de sensibilidade univariada para a avaliação das incertezas do modelo e
        dos valores assumidos devido à escassez de dados na literatura. Para tal, as probabilidades
        de transição e os custos foram variados entre 10% menos e 10% mais.</p>
    </sec>
    <sec sec-type="results">
      <title>RESULTADOS</title>
      <p>Ao final da coorte, os tratamentos iniciados com ETV e TDF apresentaram maiores proporções
        de pacientes com desfecho de eficácia. Respectivamente, 44,0% e 44,3% dos pacientes
        HBeAg-positivo obtiveram soroconversão HBeAg. Para os pacientes HBeAg-negativo, 17,7% do
        grupo tratado inicialmente com ETV e 18,3% dos inicialmente tratados com TDF tiveram níveis
        indetectáveis de DNA do VHB ( <xref ref-type="table" rid="t03">Tabela 3</xref> ).</p>
      <p>
        <table-wrap id="t03">
          <label>Tabela 3</label>
          <caption>
            <title>Proporções de pacientes em cada estado da doença ao final da coorte, de acordo
              com tratamento.</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="10%">
              <col width="30%"/>
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <tbody>
              <tr>
                <td rowspan="3">Tratamento</td>
                <td colspan="7" align="center">Proporção</td>
              </tr>
              <tr>
                <td colspan="7" style="border-bottom: thin solid; border-color: #000000"/>
              </tr>
              <tr>
                <td align="center">Resposta <sup>a</sup></td>
                <td align="center">Sem alteração</td>
                <td align="center">Resistência</td>
                <td align="center">CC</td>
                <td align="center">CD</td>
                <td align="center">CHC</td>
                <td align="center">Óbito</td>
              </tr>
              <tr>
                <td colspan="8" style="border-bottom: thin solid; border-color: #000000"/>
              </tr>
              <tr>
                <td>HBeAg-positivo</td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
              </tr>
              <tr>
                <td> ADV</td>
                <td align="center">0,314</td>
                <td align="center">&lt; 0,000</td>
                <td align="center">0,023</td>
                <td align="center">0,050</td>
                <td align="center">0,007</td>
                <td align="center">0,003</td>
                <td align="center">0,604</td>
              </tr>
              <tr>
                <td> ETV</td>
                <td align="center">0,440</td>
                <td align="center">&lt; 0,000</td>
                <td align="center">0,001</td>
                <td align="center">0,043</td>
                <td align="center">0,005</td>
                <td align="center">0,002</td>
                <td align="center">0,508</td>
              </tr>
              <tr>
                <td> LAM</td>
                <td align="center">0,240</td>
                <td align="center">&lt; 0,000</td>
                <td align="center">0,034</td>
                <td align="center">0,052</td>
                <td align="center">0,007</td>
                <td align="center">0,003</td>
                <td align="center">0,663</td>
              </tr>
              <tr>
                <td> TDF</td>
                <td align="center">0,443</td>
                <td align="center">&lt; 0,000</td>
                <td align="center">0,000</td>
                <td align="center">0,043</td>
                <td align="center">0,005</td>
                <td align="center">0,002</td>
                <td align="center">0,506</td>
              </tr>
              <tr>
                <td>HBeAg-negativo</td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
              </tr>
              <tr>
                <td> ADV</td>
                <td align="center">0,094</td>
                <td align="center">&lt; 0,000</td>
                <td align="center">0,012</td>
                <td align="center">0,037</td>
                <td align="center">0,005</td>
                <td align="center">0,004</td>
                <td align="center">0,847</td>
              </tr>
              <tr>
                <td> ETV</td>
                <td align="center">0,180</td>
                <td align="center">0,006</td>
                <td align="center">&lt; 0,000</td>
                <td align="center">0,036</td>
                <td align="center">0,005</td>
                <td align="center">0,004</td>
                <td align="center">0,768</td>
              </tr>
              <tr>
                <td> LAM</td>
                <td align="center">0,110</td>
                <td align="center">&lt; 0,000</td>
                <td align="center">0,013</td>
                <td align="center">0,037</td>
                <td align="center">0,005</td>
                <td align="center">0,004</td>
                <td align="center">0,831</td>
              </tr>
              <tr>
                <td> TDF</td>
                <td align="center">0,183</td>
                <td align="center">0,007</td>
                <td align="center">0,000</td>
                <td align="center">0,036</td>
                <td align="center">0,005</td>
                <td align="center">0,003</td>
                <td align="center">0,766</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>ADV: adefovir; CC: cirrose compensada; CD: cirrose descompensada; CHC: carcinoma
              hepatocelular; ETV: entecavir; LAM: lamivudina; TDF: tenofovir</p>
            <p>
              <sup>a</sup> Em pacientes HBeAg-positivo, resposta foi definida como soroconversão
              HBeAg. Em pacientes HBeAg-negativo, resposta foi definida como níveis indetectáveis de
              DNA do vírus da hepatite B.</p>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>Os mesmos tratamentos foram mais protetores em relação às complicações da doença. Para o
        grupo inicialmente tratado com ETV, 44,1% dos pacientes HBeAg-positivo e 18,2% dos
        HBeAg-negativo não evoluíram para CC, CD, CHC, óbito ou resistência viral ao tratamento.
        Considerando o grupo inicialmente tratado com TDF, 44,4% dos pacientes HBeAg-positivo e
        19,0% dos HBeAg-negativo não evoluíram para tais complicações.</p>
      <p>O tratamento com ADV proporcionou os maiores custos e os piores resultados. Essa
        alternativa foi, portanto, dominada pelas demais estratégias. Considerando desconto de 5%
        nos custos e efeitos, para pacientes HBeAg-positivo o tratamento com LAM também foi dominado
        por ETV e TDF. Nesses pacientes, observou-se menor RCE para ETV (R$ 4.010,84/AVG) em relação
        ao TDF (R$ 4.140,57/AVG). A RCEI de TDF em relação ao ETV (R$ 162.735,04/AVG) foi maior que
        o triplo do PIB <italic>per capita</italic> brasileiro. Para pacientes HBeAg-negativo, o
        tratamento com LAM proporcionou o menor RCE (R$ 6.205,08/AVG), seguido de ETV (R$
        6.532,04/AVG) e TDF (R$ 6.651,64/AVG). A RCEI de ETV em relação à LAM (R$ 18.065,14/AVG) foi
        menor que o PIB <italic>per capita</italic> do Brasil. Comparado ao ETV, TDF apresentou RCEI
        de R$ 71.956,13 por AVG, que é maior que o limiar sugerido pela OMS ( <xref ref-type="table"
          rid="t04">Tabela 4</xref> ).</p>
      <p>
        <table-wrap id="t04">
          <label>Tabela 4</label>
          <caption>
            <title>Resultados de custo-efetividade considerando desconto de 5% nos custos e
              efeitos.</title>
          </caption>
          <table frame="hsides" rules="groups">
            <colgroup width="14%">
              <col width="15%"/>
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
              <col/>
            </colgroup>
            <tbody>
              <tr>
                <td>Tratamento <sup>a</sup></td>
                <td align="center">Custo (R$)</td>
                <td align="center">Custo incremental (R$) <sup>b</sup></td>
                <td align="center">Efetividade (AVG)</td>
                <td align="center">Efetividade incremental (AVG) <sup>b</sup></td>
                <td align="center">RCE (R$/AVG)</td>
                <td align="center">RCEI (R$/AVG) <sup>b</sup></td>
              </tr>
              <tr>
                <td colspan="7" style="border-bottom: thin solid; border-color: #000000"/>
              </tr>
              <tr>
                <td>HBeAg-positivo</td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
              </tr>
              <tr>
                <td> ETV</td>
                <td align="center">57.401,84</td>
                <td> </td>
                <td align="center">14,31</td>
                <td> </td>
                <td align="center">4.010,84</td>
                <td> </td>
              </tr>
              <tr>
                <td> TDF</td>
                <td align="center">59.307,01</td>
                <td align="center">1.905,17</td>
                <td align="center">14,32</td>
                <td align="center">0,01</td>
                <td align="center">4.140,57</td>
                <td align="center">162.735,04</td>
              </tr>
              <tr>
                <td> LAM</td>
                <td align="center">66.937,69</td>
                <td align="center">7.630,69</td>
                <td align="center">13,59</td>
                <td align="center">-0,74</td>
                <td align="center">4.927,27</td>
                <td align="center">(Dominado)</td>
              </tr>
              <tr>
                <td> ADV</td>
                <td align="center">80.484,43</td>
                <td align="center">21.177,42</td>
                <td align="center">13,85</td>
                <td align="center">-0,47</td>
                <td align="center">5.811,16</td>
                <td align="center">(Dominado)</td>
              </tr>
              <tr>
                <td>HBeAg-negativo</td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
                <td> </td>
              </tr>
              <tr>
                <td> LAM</td>
                <td align="center">74.900,36</td>
                <td> </td>
                <td align="center">12,07</td>
                <td> </td>
                <td align="center">6.205,08</td>
                <td> </td>
              </tr>
              <tr>
                <td> ETV</td>
                <td align="center">81.082,47</td>
                <td align="center">4.915,76</td>
                <td align="center">12,42</td>
                <td align="center">0,35</td>
                <td align="center">6.426,71</td>
                <td align="center">14.101,05</td>
              </tr>
              <tr>
                <td> TDF</td>
                <td align="center">82.718,16</td>
                <td align="center">2.902,05</td>
                <td align="center">12,44</td>
                <td align="center">0,02</td>
                <td align="center">6.651,64</td>
                <td align="center">177.658,84</td>
              </tr>
              <tr>
                <td> ADV</td>
                <td align="center">103.608,92</td>
                <td align="center">20.890,76</td>
                <td align="center">11,92</td>
                <td align="center">-0,52</td>
                <td align="center">8.693,69</td>
                <td align="center">(Dominado)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <p>ADV: adefovir; AVG: anos de vida ganhos; ETV: entecavir; LAM: lamivudina; RCE: razão
              custo-efetividade; RCEI: razão custo-efetividade incremental</p>
            <p>
              <sup>a</sup> Tratamentos listados em ordem crescente de custo, de acordo com o subtipo
              da doença.</p>
            <p>
              <sup>b</sup> Valores em relação ao medicamento não dominado com custo mais
              próximo.</p>
            <p>Taxa de câmbio em 29/12/2011: US$ 1,00 = R$ 1,87.</p>
          </table-wrap-foot>
        </table-wrap>
      </p>
      <p>Analisando cenário sem aplicação de descontos, para pacientes HBeAg-positivo a RCE de ETV
        (R$ 3.141,17/AVG) foi menor em relação à do TDF (R$ 3.219,87/AVG). A RCEI de TDF em relação
        ao ETV foi de R$ 52.966,58 por AVG. Para pacientes HBeAg-negativo, o tratamento com LAM foi
        dominado por ETV e TDF. A RCE de ETV (R$ 5.894,36/AVG) foi menor em relação à do TDF (R$
        6.079,00/AVG). A RCEI de TDF em relação ao ETV foi de R$ 81.081,06 por AVG.</p>
      <p>Considerando cenário com desconto de 10% nos custos e efeitos, para pacientes
        HBeAg-positivo a RCE foi de R$ 4.665,08/AVG e R$ 4.838,21/AVG para ETV e TDF,
        respectivamente. A RCEI de TDF em relação ao ETV foi de R$ 433.119,83 por AVG. Para
        pacientes HBeAg-negativo, a menor RCE foi para o tratamento com LAM (R$ 5.999,10/AVG),
        seguido de ETV (R$ 6.701,40/AVG) e TDF (R$ 6.953,76/AVG). A RCEI de ETV em relação a LAM foi
        de R$ 55.668,84 por AVG. Considerando TDF em relação ao ETV, a RCEI foi de R$ 354.997,16 por
        AVG.</p>
      <p>De acordo com a análise de sensibilidade, para pacientes HBeAg-positivo a variação dos
        custos dos antivirais ao longo da coorte pode tornar a RCEI menor que o limiar sugerido pela
        OMS. Para pacientes HBeAg-negativo, a variação dos custos dos antivirais, tanto no primeiro
        ano quanto nos subsequentes, também pode tornar menor que o triplo do PIB <italic>per
          capita</italic> brasileiro a RCEI de TDF em relação ao ETV. A alteração das variáveis
        consideradas no modelo para pacientes HBeAg-negativo não faz com que a RCEI de ETV em
        relação à LAM seja maior que três vezes o PIB <italic>per capita</italic> do Brasil ( <xref
          ref-type="fig" rid="f01">Figura</xref> ).</p>
      <p>
        <fig id="f01">
          <label>Figura 1</label>
          <caption>
            <title>Análise de sensibilidade univariada entre as estratégias de tratamento não
              dominadas. A) TDF <italic>versus</italic> ETV, HBeAg-positivo; B) ETV
                <italic>versus</italic> LAM, HBeAg-negativo; C) TDF versus LAM, HBeAg-negativo; D)
              TDF <italic>versus</italic> ETV, HBeAg-negativo.</title>
          </caption>
          <graphic xlink:href="0034-8910-rsp-47-04-0769-gf01"/>
        </fig>
      </p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSÃO</title>
      <p>Considerando as evidências clínicas utilizadas e o custo definido pela CMED para os
        análogos de nucleos(t)ídeos, iniciar o tratamento com ETV é a alternativa mais custo-efetiva
        para o tratamento da HBC em pacientes HBeAg-positivo e é custo-efetiva, comparado à LAM,
        para pacientes HBeAg-negativo.</p>
      <p>Em pacientes HBeAg-positivo, iniciar o tratamento com LAM proporciona maiores custos e
        menores valores de AVG em relação a ETV e TDF, caracterizando-se uma alternativa dominada.
        Para ambos os subtipos da doença, iniciar o tratamento com ADV também é uma alternativa
        dominada por ETV e TDF. Essas alternativas dominadas não são recomendadas para iniciar o
        tratamento.</p>
      <p>A RCE de ETV foi a menor em relação às dos demais tratamentos para pacientes
        HBeAg-positivo, definindo um custo de R$ 4.010,84 para cada AVG. Considerando o tratamento
        com TDF, seria necessário investimento incremental de R$ 162.735,04 por AVG adicional.
        Apesar de este valor ser maior que o limiar estabelecido pela OMS, a análise de
        sensibilidade indica que essa situação pode se reverter de acordo com a redução do custo
        desse medicamento ou com o aumento do custo de ETV. Considerando essas variações de custo, o
        tratamento inicial com TDF também pode ser considerado a alternativa mais custo-efetiva.</p>
      <p>Em pacientes HBeAg-negativo, a menor RCE foi a do tratamento iniciado com LAM. Para
        alcançar um AVG a mais com ETV em relação ao tratamento com LAM, é necessário investimento
        incremental de R$ 18.065,14. Esse valor é menor que o limiar sugerido pela OMS, de três
        vezes o PIB <italic>per capita</italic> nacional, que caracteriza o ETV como alternativa
        custo-efetiva. Com relação ao tratamento iniciado com TDF, seriam necessários investimentos
        incrementais de R$ 21.421,93 e R$ 71.956,13 para cada AVG em relação, respectivamente, ao
        tratamento com LAM e ETV. A análise de sensibilidade mostra que, considerando variações nos
        custos de ETV e TDF, este também pode se apresentar como alternativa custo-efetiva.</p>
      <p>Com ligeira superioridade em relação ao ETV, o modelo indica que o tratamento inicial com
        TDF proporciona melhores resultados clínicos em relação aos demais tratamentos. Com esse
        tratamento, observaram-se maior probabilidade de obtenção do desfecho de eficácia e menor
        probabilidade de progressão para complicações da HBC.</p>
      <p>Modelos econômicos são simplificações da realidade. A complexidade multifatorial do
        tratamento de uma enfermidade não será, dessa forma, totalmente abordada. As análises
        econômicas fornecem subsídios para as decisões dos atores responsáveis pela coordenação dos
        programas e serviços de saúde. Essas decisões devem ter em conta os fatores e premissas
        considerados no modelo, bem como os não modelados. Dessa forma, algumas limitações podem ser
        identificadas neste estudo, como obtenção de valores de custo por fontes secundárias, dados
        de eficácia e efetividade obtidos de estudos sobre populações internacionais, seleção
        arbitrária de estudos para a composição do modelo e extrapolação de dados clínicos, taxas de
        resistência e terapia de resgate.</p>
      <p>A perspectiva adotada para a análise de custo-efetividade foi a do sistema público de saúde
        brasileiro. Contudo, os dados de custos considerados não foram obtidos a partir de bases de
        dados nacionais, como o Sistema de Informações Ambulatoriais. Outra limitação do presente
        estudo refere-se aos dados de eficácia e de progressão da doença, que foram extraídos de
        estudos cujas populações não compreendiam pacientes brasileiros. Esses dados foram
        utilizados devido à escassez de estudos clínicos dessa doença no contexto nacional. Também
        são escassos estudos clínicos prospectivos para a HBC, devido à necessidade de longo período
        de acompanhamento. Dessa forma, os dados clínicos de resposta ao tratamento foram
        extrapolados ao final da coorte hipotética.</p>
      <p>São escassas as estimativas de efetividade para terapias de resgate após um ano de
        tratamento. Portanto, a avaliação dos dados obtidos para substituição de alguma alternativa
        terapêutica devido à resistência viral deve ser abordada com cautela.</p>
      <p>Análises de custo-utilidade sob a perspectiva de serviços de saúde de outros países
        apontaram TDF como alternativa mais custo-efetiva em relação a ETV e LAM. Um estudo adotando
        a perspectiva espanhola apontou o tratamento com TDF responsável por maior expectativa de
        vida e menores custos em relação aos demais tratamentos. <xref ref-type="bibr" rid="B1">
          <sup>1</sup>
        </xref> Estudo realizado sob a perspectiva do serviço nacional de saúde italiano concluiu
        que TDF é a alternativa mais custo-efetiva. <xref ref-type="bibr" rid="B6">
          <sup>6</sup>
        </xref> Em ambos os estudos, o custo anual desse medicamento foi menor em relação aos demais
        análogos de nucleos(t)ídeos, variando de 66,6% a 73,2% do custo anual de ETV. No Brasil, de
        acordo com os valores estabelecidos pela CMED, o custo anual de TDF equivale a 107,9% do
        custo de ETV. Em consonância com os resultados do presente estudo, análise de
        custo-efetividade comparando ETV e LAM sob a perspectiva do sistema público de saúde
        brasileiro concluiu que o tratamento com ETV é a alternativa mais custo-efetiva. <xref
          ref-type="bibr" rid="B7">
          <sup>7</sup>
        </xref>
      </p>
      <p>A análise de sensibilidade possibilitou avaliar as incertezas numa variação de 10% em torno
        de cada valor utilizado, o que permitiu considerações sobre a robustez dos resultados do
        estudo em relação aos pressupostos adotados. Foi possível definir que a RCEI é mais sensível
        às variações no custo dos medicamentos. Considerando a variação proposta, observamos
        cenários nos quais ETV e TDF podem ser considerados custo-efetivos e com RCEI abaixo do
        limiar recomendado para incorporação de tecnologias no Brasil.</p>
      <p>Considerando a produção científica atualmente disponível, a avaliação reitera a
        incorporação e priorização de ETV e TDF no rol de análogos de nucleos(t)ídeos do protocolo
        clínico e diretrizes terapêuticas da HBC. Algumas iniciativas podem ser importantes na
        redução do preço desses medicamentos. Uma delas pode ser o incentivo à utilização dos
        laboratórios oficiais na produção de medicamentos com custos reduzidos em relação ao mercado
        privado. Isso pode permitir que o tratamento com TDF, que apresentou melhores resultados
        clínicos, também se comporte com melhores resultados de custo-efetividade em relação ao ETV.
        Essa ação proporcionaria melhor tratamento à população afetada pela HBC.</p>
      <p>Dentre os antivirais considerados, ETV e TDF apresentaram os melhores resultados clínicos.
        Para pacientes HBeAg-positivo, são as alternativas mais custo-efetivas. Para pacientes
        HBeAg-negativo, mostram custo-efetividade aceitável para serem utilizadas no Brasil. Dessa
        forma, considerando a perspectiva do SUS e os dados do modelo, a utilização de ETV e TDF são
        alternativas recomendadas para iniciar o tratamento de HBC em pacientes adultos e sem
        coinfecção por HIV. Para o reforço desse achado, são necessários mais estudos clínicos –
        principalmente em população brasileira – e estudos de impacto orçamentário.</p>
    </sec>
  </body>
  <back>
    <app-group>
      <p>DESTAQUES</p>
      <p>Considerando a restrição de recursos para a saúde, o aumento da expectativa de vida, o
        aumento da idade média da população, a maior prevalência de agravos crônicos em relação aos
        não crônicos e o surgimento crescente de inovações farmacêuticas, a utilização de
        conhecimentos e métodos farmacoeconômicos torna-se indispensável. Os gastos com
        financiamento de medicamentos do Componente Especializado da Assistência Farmacêutica têm
        mostrado tendência ininterrupta de crescimento no Sistema Único de Saúde, variando de R$ 685
        milhões em 2000 (R$ 4,01 <italic>per capita</italic> ) para R$ 1,41 bilhão em 2007 (R$ 7,40
          <italic>per capita</italic> ). Essa situação gera a necessidade de racionalização e
        otimização dos recursos financeiros destinados à assistência farmacêutica.</p>
      <p>A utilização de antivirais para o tratamento de pacientes com hepatite B crônica no Brasil
        se dá sem que haja estudos farmacoeconômicos para esse contexto. Este artigo utilizou-se de
        uma coorte hipotética de pacientes com hepatite crônica, com e sem positividade para HBeAg,
        para analisar o custo efetividade de diferentes alternativas terapêuticas. Como desfecho
        foram utilizados os anos de vida ganhos em cada uma das alternativas.</p>
      <p>Com os preços atuais os tratamentos com maior custo-efetividade foram entecavir para
        pacientes HBeAg positivo e lamivudina para pacientes HBeAg negativos.</p>
      <p>Profa. Rita de Cássia Barradas Barata Editora Científica</p>
    </app-group>
    <ref-list>
      <title>REFERÊNCIAS</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>. Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the
          cost-effectiveness of different oral antiviral therapies in patients with chronic
          hepatitis B. <italic>J Hepatol</italic> . 2009;51(4):640-6.
          DOI:10.1016/j.jhep.2009.04.013.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Buti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brosa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Casado</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Rueda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Esteban</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Modeling the cost-effectiveness of different oral antiviral
            therapies in patients with chronic hepatitis B</article-title>
          <source>J Hepatol</source>
          <year>2009</year>
          <volume>51</volume>
          <issue>4</issue>
          <fpage>640</fpage>
          <lpage>646</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jhep.2009.04.013</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>. Carias CM, Vieira FS, Giordano CV, Zucchi P. Exceptional circumstance drug
          dispensing: history and expenditures of the Brazilian Ministry of Health. <italic>Rev
            Saude Publica</italic> . 2011;45(2):233-40.
          DOI:10.1590/S0034-89102011000200001</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Carias</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Vieira</surname>
              <given-names>FS</given-names>
            </name>
            <name>
              <surname>Giordano</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Zucchi</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Exceptional circumstance drug dispensing: history and
            expenditures of the Brazilian Ministry of Health</article-title>
          <source>Rev Saude Publica</source>
          <year>2011</year>
          <volume>45</volume>
          <issue>2</issue>
          <fpage>233</fpage>
          <lpage>240</lpage>
          <pub-id pub-id-type="doi">10.1590/S0034-89102011000200001</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>. Castelo A, Pessôa MG, Barreto TCBB, Alves MRD, Araújo DV. Estimativas de
          custo da hepatite crônica B no Sistema Único de Saúde brasileiro em 2005. <italic>Rev
            Assoc Med Bras</italic> . 2007;53(6):486-91.
          DOI:10.1590/S0104-42302007000600013</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Castelo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pessôa</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Barreto</surname>
              <given-names>TCBB</given-names>
            </name>
            <name>
              <surname>Alves</surname>
              <given-names>MRD</given-names>
            </name>
            <name>
              <surname>Araújo</surname>
              <given-names>DV</given-names>
            </name>
          </person-group>
          <article-title xml:lang="pt">Estimativas de custo da hepatite crônica B no Sistema Único
            de Saúde brasileiro em 2005</article-title>
          <source>Rev Assoc Med Bras</source>
          <year>2007</year>
          <volume>53</volume>
          <issue>6</issue>
          <fpage>486</fpage>
          <lpage>491</lpage>
          <pub-id pub-id-type="doi">10.1590/S0104-42302007000600013</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>. Chang TT, Gish RG, Man R, Gadano A, Sollano J, Chao YC, et al. A
          comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. <italic>N
            Engl J Med</italic> . 2006;354(10):1001-10. DOI:10.1056/NEJMoa051285</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Chang</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Gish</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Man</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gadano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sollano</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chao</surname>
              <given-names>YC</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">A comparison of entecavir and lamivudine for HBeAg-positive
            chronic hepatitis B</article-title>
          <source>N Engl J Med</source>
          <year>2006</year>
          <volume>354</volume>
          <issue>10</issue>
          <fpage>1001</fpage>
          <lpage>1010</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa051285</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>. Chen EQ, Wang LC, Lei J, Xu L, Tang H. Meta-analysis: adefovir dipivoxil
          in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.
            <italic>Virol J</italic> . 2009;6:163. DOI:10.1186/1743-422X-6-163</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Chen</surname>
              <given-names>EQ</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Lei</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Meta-analysis: adefovir dipivoxil in combination with
            lamivudine in patients with lamivudine-resistant hepatitis B virus</article-title>
          <source>Virol J</source>
          <year>2009</year>
          <volume>6</volume>
          <size units="pages">163</size>
          <pub-id pub-id-type="doi">10.1186/1743-422X-6-163</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>. Colombo GL, Gaeta GB, Viganò M, Di Matteo S. A cost-effectiveness analysis
          of different therapies in patients with chronic hepatitis B in Italy. <italic>Clinicoecon
            Outcomes Res</italic> . 2011;3:37-46. DOI:10.2147/CEOR.S16655</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Colombo</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Gaeta</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>Viganò</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Di Matteo</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">A cost-effectiveness analysis of different therapies in
            patients with chronic hepatitis B in Italy</article-title>
          <source>Clinicoecon Outcomes Res</source>
          <year>2011</year>
          <volume>3</volume>
          <fpage>37</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.2147/CEOR.S16655</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>. Costa AM, L’Italien G, Nita ME, Araujo ES. Cost-effectiveness of entecavir
          versus lamivudine for the suppression of viral replication in chronic hepatitis B patients
          in Brazil. <italic>Braz J Infect Dis</italic> . 2008;12(5):368-73.
          DOI:10.1590/S1413-86702008000500005</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Costa</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>L’Italien</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Nita</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Araujo</surname>
              <given-names>ES</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Cost-effectiveness of entecavir versus lamivudine for the
            suppression of viral replication in chronic hepatitis B patients in
            Brazil</article-title>
          <source>Braz J Infect Dis</source>
          <year>2008</year>
          <volume>12</volume>
          <issue>5</issue>
          <fpage>368</fpage>
          <lpage>373</lpage>
          <pub-id pub-id-type="doi">10.1590/S1413-86702008000500005</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>. Crowley S, Tognarini D, Desmond P, Lees M, Saal G. Introduction of
          lamivudine for the treatment of chronic hepatitis B: expected clinical and economic
          outcomes based on 4-year clinical trial data. <italic>J Gastroenterol Hepatol</italic> .
          2002;17(2):153-64. DOI:10.1046/j.1440-1746.2002.02673.x</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Crowley</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tognarini</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Desmond</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lees</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saal</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Introduction of lamivudine for the treatment of chronic
            hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial
            data</article-title>
          <source>J Gastroenterol Hepatol</source>
          <year>2002</year>
          <volume>17</volume>
          <issue>2</issue>
          <fpage>153</fpage>
          <lpage>164</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1440-1746.2002.02673.x</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>. Crowley SJ, Tognarini D, Desmond PV, Lees M. Cost-effectiveness analysis
          of lamivudine for the treatment of chronic hepatitis B. <italic>Pharmacoeconomics</italic>
          . 2000;17(5):409-27.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Crowley</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Tognarini</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Desmond</surname>
              <given-names>PV</given-names>
            </name>
            <name>
              <surname>Lees</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Cost-effectiveness analysis of lamivudine for the treatment
            of chronic hepatitis B</article-title>
          <source>Pharmacoeconomics</source>
          <year>2000</year>
          <volume>17</volume>
          <issue>5</issue>
          <fpage>409</fpage>
          <lpage>427</lpage>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation>. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH
          conference. Hepatocellular carcinoma. <italic>Ann Intern Med</italic> .
          1988;108(3):390-401. DOI:10.7326/0003-4819-108-3-390</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Di Bisceglie</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Rustgi</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Hoofnagle</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Dusheiko</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Lotze</surname>
              <given-names>MT</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">NIH conference. Hepatocellular carcinoma</article-title>
          <source>Ann Intern Med</source>
          <year>1988</year>
          <volume>108</volume>
          <issue>3</issue>
          <fpage>390</fpage>
          <lpage>401</lpage>
          <pub-id pub-id-type="doi">10.7326/0003-4819-108-3-390</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation>. European Association for the Study of the Liver. EASL clinical practice
          guidelines: management of chronic hepatitis B. <italic>J Hepatol</italic> .
          2009;50(2):227-42. DOI:10.1016/j.jhep.2008.10.001</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <collab>European Association for the Study of the Liver</collab>
          </person-group>
          <article-title xml:lang="en">EASL clinical practice guidelines: management of chronic
            hepatitis B</article-title>
          <source>J Hepatol</source>
          <year>2009</year>
          <volume>50</volume>
          <issue>2</issue>
          <fpage>227</fpage>
          <lpage>242</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jhep.2008.10.001</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation>. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et
          al. Natural history and prognostic factors for chronic hepatitis type B.
            <italic>Gut</italic> . 1991;32(3):294-8.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Fattovich</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brollo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Giustina</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Noventa</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pontisso</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Alberti</surname>
              <given-names>A</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Natural history and prognostic factors for chronic hepatitis
            type B</article-title>
          <source>Gut</source>
          <year>1991</year>
          <volume>32</volume>
          <issue>3</issue>
          <fpage>294</fpage>
          <lpage>298</lpage>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation>. Ganem D, Prince AM. Hepatitis B virus infection: natural history and
          clinical consequences. <italic>N Engl J Med</italic> . 2004;350(11):1118-29.
          DOI:10.1056/NEJMra031087</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Ganem</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Prince</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Hepatitis B virus infection: natural history and clinical
            consequences</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>350</volume>
          <issue>11</issue>
          <fpage>1118</fpage>
          <lpage>1129</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMra031087</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation>. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto
          M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic
          hepatitis B. <italic>N Engl J Med</italic> . 2003;27;348(9):800-7.
          DOI:10.1056/NEJMoa021812</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Hadziyannis</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Tassopoulos</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Heathcote</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Kitis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rizzetto</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Adefovir dipivoxil for the treatment of hepatitis B e
            antigen-negative chronic hepatitis B</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>348</volume>
          <issue>9</issue>
          <fpage>800</fpage>
          <lpage>807</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa021812</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation>. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto
          M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis
          B. <italic>N Engl J Med</italic> . 2005;352(26):2673-81.
          DOI:10.1056/NEJMoa042957</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Hadziyannis</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Tassopoulos</surname>
              <given-names>NC</given-names>
            </name>
            <name>
              <surname>Heathcote</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Kitis</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Rizzetto</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Long-term therapy with adefovir dipivoxil for HBeAg-negative
            chronic hepatitis B</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>352</volume>
          <issue>26</issue>
          <fpage>2673</fpage>
          <lpage>2681</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa042957</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <mixed-citation>. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al.
          Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
            <italic>N Engl J Med</italic> . 2006;354(10):1011-20.
          DOI:10.1056/NEJMoa051287</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Lai</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Shouval</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lok</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Cheinquer</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Goodman</surname>
              <given-names>Z</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Entecavir versus lamivudine for patients with HBeAg-negative
            chronic hepatitis B</article-title>
          <source>N Engl J Med</source>
          <year>2006</year>
          <volume>354</volume>
          <issue>10</issue>
          <fpage>1011</fpage>
          <lpage>1020</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa051287</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <mixed-citation>. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, et al.
          Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.
            <italic>Gastroenterology</italic> . 1997;113(5):1660-7.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Lau</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Everhart</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kleiner</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Vergalla</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schmid</surname>
              <given-names>P</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Long-term follow-up of patients with chronic hepatitis B
            treated with interferon alfa</article-title>
          <source>Gastroenterology</source>
          <year>1997</year>
          <volume>113</volume>
          <issue>5</issue>
          <fpage>1660</fpage>
          <lpage>1667</lpage>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <mixed-citation>. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et
          al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic
          hepatitis B. <italic>N Engl J Med</italic> . 2005;352(26):2682-95.
          DOI:10.1056/NEJMoa043470</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Lau</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Piratvisuth</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>KX</given-names>
            </name>
            <name>
              <surname>Marcellin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Thongsawat</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cooksley</surname>
              <given-names>G</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Peginterferon Alfa-2a, lamivudine, and the combination for
            HBeAg-positive chronic hepatitis B</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>352</volume>
          <issue>26</issue>
          <fpage>2682</fpage>
          <lpage>2695</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa043470</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <mixed-citation>. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients
          with chronic type B hepatitis: a prospective study. <italic>Hepatology.</italic>
          1988;8(3):493-6.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Liaw</surname>
              <given-names>YF</given-names>
            </name>
            <name>
              <surname>Tai</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>TJ</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">The development of cirrhosis in patients with chronic type B
            hepatitis: a prospective study</article-title>
          <source>Hepatology</source>
          <year>1988</year>
          <volume>8</volume>
          <issue>3</issue>
          <fpage>493</fpage>
          <lpage>496</lpage>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <mixed-citation>. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine
          for patients with chronic hepatitis B and advanced liver disease. <italic>N Engl J
            Med</italic> . 2004;351(15):1521-31. DOI:10.1056/NEJMoa033364</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Liaw</surname>
              <given-names>YF</given-names>
            </name>
            <name>
              <surname>Sung</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Farrell</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CZ</given-names>
            </name>
            <name>
              <surname>Yuen</surname>
              <given-names>H</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Lamivudine for patients with chronic hepatitis B and advanced
            liver disease</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>351</volume>
          <issue>15</issue>
          <fpage>1521</fpage>
          <lpage>1531</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa033364</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <mixed-citation>. Lok AS, McMahon BJ. Chronic hepatitis B. <italic>Hepatology</italic> .
          2007;45(2):507-39. DOI:10.1002/hep.21513</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Lok</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>McMahon</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Chronic hepatitis B</article-title>
          <source>Hepatology</source>
          <year>2007</year>
          <volume>45</volume>
          <issue>2</issue>
          <fpage>507</fpage>
          <lpage>539</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.21513</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <mixed-citation>. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al.
          Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis
          B. <italic>N Engl J Med</italic> . 2003;348(9):808-16.
          DOI:10.1056/NEJMoa020681</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Marcellin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Tong</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Sievert</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Shiffman</surname>
              <given-names>ML</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Adefovir dipivoxil for the treatment of hepatitis B e
            antigen-positive chronic hepatitis B</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>348</volume>
          <issue>9</issue>
          <fpage>808</fpage>
          <lpage>816</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa020681</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <mixed-citation>. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al.
          Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with
          HBeAg-negative chronic hepatitis B. <italic>N Engl J Med</italic> . 2004;351(12):1206-17.
          DOI:10.1056/NEJMoa040431</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Marcellin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Bonino</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Farci</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hadziyannis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>R</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Peginterferon alfa-2a alone, lamivudine alone, and the two in
            combination in patients with HBeAg-negative chronic hepatitis B</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>351</volume>
          <issue>12</issue>
          <fpage>1206</fpage>
          <lpage>1217</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa040431</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <mixed-citation>. Marcellin P, Heathcote EJ, Buti M, Gane E, Man RA, Krastev Z, et al.
          Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. <italic>N
            Engl J Med</italic> . 2008;359(23):2442-55. DOI:10.1056/NEJMoa0802878</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Marcellin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Heathcote</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Buti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gane</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Man</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Krastev</surname>
              <given-names>Z</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic
            hepatitis B</article-title>
          <source>N Engl J Med</source>
          <year>2008</year>
          <volume>359</volume>
          <issue>23</issue>
          <fpage>2442</fpage>
          <lpage>2455</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa0802878</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <mixed-citation>. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e
          antigen in hepatitis B virus infection. <italic>Hepatology</italic> . 2003;38(5):1075-86.
          DOI:10.1053/jhep.2003.50453</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Milich</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>TJ</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Exploring the biological basis of hepatitis B e antigen in
            hepatitis B virus infection</article-title>
          <source>Hepatology</source>
          <year>2003</year>
          <volume>38</volume>
          <issue>5</issue>
          <fpage>1075</fpage>
          <lpage>1086</lpage>
          <pub-id pub-id-type="doi">10.1053/jhep.2003.50453</pub-id>
        </element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <mixed-citation>. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al.
          Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant
          hepatitis B virus. <italic>Gastroenterology</italic> . 2004;126(1):81-90.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Perrillo</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hann</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Mutimer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Willems</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>WM</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Adefovir dipivoxil added to ongoing lamivudine in chronic
            hepatitis B with YMDD mutant hepatitis B virus</article-title>
          <source>Gastroenterology</source>
          <year>2004</year>
          <volume>126</volume>
          <issue>1</issue>
          <fpage>81</fpage>
          <lpage>90</lpage>
        </element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <mixed-citation>. Pwu RF, Chan KA. Cost-effectiveness analysis of interferon-alpha therapy
          in the treatment of chronic hepatitis B in Taiwan. <italic>J Formos Med Assoc</italic> .
          2002;101(9):632-41.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Pwu</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>KA</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Cost-effectiveness analysis of interferon-alpha therapy in
            the treatment of chronic hepatitis B in Taiwan</article-title>
          <source>J Formos Med Assoc</source>
          <year>2002</year>
          <volume>101</volume>
          <issue>9</issue>
          <fpage>632</fpage>
          <lpage>641</lpage>
        </element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <mixed-citation>. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias
          J, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type
          B: a multicenter study. The Investigators of the European Concerted Action on Viral
          Hepatitis (EUROHEP). <italic>J Hepatol</italic> . 1994;21(4):656-66.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Realdi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fattovich</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hadziyannis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schalm</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Almasio</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sanchez-Tapias</surname>
              <given-names>J</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title xml:lang="en">Survival and prognostic factors in 366 patients with
            compensated cirrhosis type B: a multicenter study. The Investigators of the European
            Concerted Action on Viral Hepatitis (EUROHEP)</article-title>
          <source>J Hepatol</source>
          <year>1994</year>
          <volume>21</volume>
          <issue>4</issue>
          <fpage>656</fpage>
          <lpage>666</lpage>
        </element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <mixed-citation>. Sonnenberg FA, Beck JR. Markov models in medical decision making: a
          practical guide. <italic>Med Decis Making</italic> . 1993;13(4):322-38.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Sonnenberg</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Markov models in medical decision making: a practical
            guide</article-title>
          <source>Med Decis Making</source>
          <year>1993</year>
          <volume>13</volume>
          <issue>4</issue>
          <fpage>322</fpage>
          <lpage>338</lpage>
        </element-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <mixed-citation>. Takeda A, Jones J, Shepherd J, Davidson P, Price A. A systematic review
          and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the
          treatment of chronic hepatitis B. <italic>J Viral Hepat</italic> . 2007;14(2):75-88.
          DOI:10.1111/j.1365-2893.2006.00808.x</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Takeda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shepherd</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">A systematic review and economic evaluation of adefovir
            dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis
            B</article-title>
          <source>J Viral Hepat</source>
          <year>2007</year>
          <volume>14</volume>
          <issue>2</issue>
          <fpage>75</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2893.2006.00808.x</pub-id>
        </element-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <mixed-citation>. Wong JB, Koff RS, Tinè F, Pauker SG. Cost-effectiveness of
          interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B.
            <italic>Ann Intern Med</italic> . 1995;122(9):664-75.
          DOI:10.7326/0003-4819-122-9-199505010-00004</mixed-citation>
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Wong</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Koff</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Tinè</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pauker</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
          <article-title xml:lang="en">Cost-effectiveness of interferon-alpha 2b treatment for
            hepatitis B e antigen-positive chronic hepatitis B</article-title>
          <source>Ann Intern Med</source>
          <year>1995</year>
          <volume>122</volume>
          <issue>9</issue>
          <fpage>664</fpage>
          <lpage>675</lpage>
          <pub-id pub-id-type="doi">10.7326/0003-4819-122-9-199505010-00004</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="supplementary-material">
        <p>Trabalho baseado na dissertação de Oliveira G.L.A., intitulada: “Avaliação econômica de
          tenofovir para o tratamento da hepatite B crônica sob a perspectiva do sistema público de
          saúde brasileiro”, apresentada à Faculdade de Medicina da Universidade Federal de Minas
          Gerais, em 2012.</p>
      </fn>
      <fn id="fn1">
        <label>a</label>
        <p>Ministério da Saúde. <italic>Bol Epidemiol Hepatites Virais.</italic> 2011;2(1):5-76.
          [citado 2011 set]. Disponível em:
          http://www.aids.gov.br/publicacao/2011/boletim_epidemiologico_hepatites_virais_2011</p>
      </fn>
      <fn id="fn2">
        <label>b</label>
        <p>Ministério da Saúde. Portaria nº 2.561, de 28 de outubro de 2009. Aprova Protocolo
          Clínico e Diretrizes Terapêuticas - Hepatite Viral Crônica B e Coinfecções. <italic>Diario
            Oficial da Uniao</italic> , Brasília, DF, 3 nov. 2009. Seção 1, p.59-71.</p>
      </fn>
      <fn id="fn3">
        <label>c</label>
        <p>
          <sup>Ministério da Saúde. Portaria nº 2.981, de 26 de novembro de 2009. Aprova o
            Componente Especializado da Assistência Farmacêutica.</sup>
          <sup>
            <italic>Diario Oficial da Uniao</italic>
          </sup>
          <sup>, Brasília, DF, 30 nov. 2009. Seção 1, p.725-771</sup>
        </p>
      </fn>
      <fn id="fn4">
        <label>d</label>
        <p>
          <sup>Taxa de câmbio em 29/12/2011: US$1,00 = R$1,87. Considerada para conversão dos
            valores monetários no estudo.</sup>
        </p>
      </fn>
      <fn id="fn5">
        <label>e</label>
        <p>
          <sup>Câmara de Regulação do Mercado de Medicamentos. Resolução nº 3, de 2 de março de
            2011.</sup>
          <sup>
            <italic>Diario Oficial da Uniao</italic>
          </sup>
          <sup>, Brasília, DF, 9 mar. 2011. Seção 1, p.3</sup>
        </p>
      </fn>
      <fn id="fn6">
        <label>f</label>
        <p>
          <sup>Abbot T. Custo em saúde, qualidade e desfechos. São Paulo: ISPOR Brasil; 2009.</sup>
        </p>
      </fn>
      <fn id="fn7">
        <label>g</label>
        <p>
          <sup>Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos,
            Departamento de Ciência e Tecnologia. Diretrizes metodológicas: estudos de avaliação
            econômica de tecnologias em saúde. Brasília (DF); 2009. (Série A. Normas e Manuais
            Técnicos)</sup>
        </p>
      </fn>
      <fn id="fn8">
        <label>h</label>
        <p>World Health Organization. Cost-effectiveness thresholds. Geneva; 2005 [cited 2011 Nov
          3]. Available from:
            http://www.who.int/choice/costs/CER_thresholds/en/index.html<sup>costs/CER_thresholds/en/index.html.</sup></p>
      </fn>
    </fn-group>
  </back>
  <sub-article article-type="translation" id="TR01" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Public Health Practice</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Incorporated antivirals for chronic hepatitis B in Brazil: a
          cost-effectiveness analysis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Oliveira</surname>
            <given-names>Gustavo Laine Araújo de</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">I</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Almeida</surname>
            <given-names>Alessandra Maciel</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">II</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silva</surname>
            <given-names>Anderson Lourenço da</given-names>
          </name>
          <xref ref-type="aff" rid="aff8">III</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Brandão</surname>
            <given-names>Cristina Mariano Ruas</given-names>
          </name>
          <xref ref-type="aff" rid="aff9">IV</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Andrade</surname>
            <given-names>Eli Iola Gurgel</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">V</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cherchiglia</surname>
            <given-names>Mariângela Leal</given-names>
          </name>
          <xref ref-type="aff" rid="aff10">V</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Acurcio</surname>
            <given-names>Francisco de Assis</given-names>
          </name>
          <xref ref-type="aff" rid="aff9">IV</xref>
        </contrib>
      </contrib-group>
      <aff id="aff6">
        <label>I</label> Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica.
        Faculdade de Farmácia. Universidade Federal de Minas Gerais. Belo Horizonte, MG,
        Brasil</aff>
      <aff id="aff7">
        <label>II</label> Departamento de Medicina Preventiva. Faculdade de Ciências Médicas de
        Minas Gerais. Belo Horizonte, MG, Brasil</aff>
      <aff id="aff8">
        <label>III</label> Superintendente de Assistência Farmacêutica e Insumos Estratégicos.
        Secretaria de Estado de Saúde. Rio de Janeiro, RJ, Brasil</aff>
      <aff id="aff9">
        <label>IV</label> Departamento de Farmácia Social. Faculdade de Farmácia. Universidade
        Federal de Minas Gerais. Belo Horizonte, MG, Brasil</aff>
      <aff id="aff10">
        <label>V</label> Departamento de Medicina Preventiva e Social. Faculdade de Medicina.
        Universidade Federal de Minas Gerais. Belo Horizonte, MG, Brasil</aff>
      <author-notes>
        <corresp>
          <label>Correspondence</label> : Gustavo Laine Araújo de Oliveira Faculdade de Farmácia
          Universidade Federal de Minas Gerais Av. Presidente Antônio Carlos, 6627 Sala 1040B2
          Pampulha 31270-901 Belo Horizonte, MG, Brasil E-mail: gustavolaine@gmail.com</corresp>
        <fn fn-type="financial-disclosure">
          <p>This research was carried out with the financial support of the <italic>Coordenação de
              Aperfeiçoamento de Pessoal de Nível Superior</italic> (CAPES), grant awarded to
            Oliveira G.L.A., together with the <italic>Conselho Nacional de Desenvolvimento
              Científico e Tecnológico</italic> (CNPq – Edital MCT/CNPq/MS-SCTIE-DECIT/CT-Saúde No.
            033/2007; CNPq – Process No. 551412/2007-0), and the <italic>Fundação de Amparo à
              Pesquisa do Estado de Minas Gerais</italic> (Fapemig).</p>
        </fn>
        <fn fn-type="conflict">
          <p>The authors declare that there are no conflicts of interest.</p>
        </fn>
      </author-notes>
      <abstract xml:lang="en">
        <sec>
          <title>OBJECTIVE</title>
          <p>To evaluate the cost-effectiveness of different drug therapies for chronic hepatitis B
            in adult patients.</p>
        </sec>
        <sec>
          <title>METHODS</title>
          <p>Using a Markov model, a hypothetical cohort of 40 years for HBeAg-positive or
            HBeAg-negative patients was constructed. Adefovir, entecavir, tenofovir and lamivudine
            (with rescue therapy in cases of viral resistance) were compared for treating adult
            patients with chronic hepatitis B undergoing treatment for the first time, with high
            levels of alanine aminotransferase, no evidence of cirrhosis and without HIV
            co-infection. Values for cost and effect were obtained from the literature, and
            expressed in effect on life years (LY). A discount rate of 5% was applied. Univariate
            sensitivity analysis was conducted to assess model uncertainties.</p>
        </sec>
        <sec>
          <title>RESULTS</title>
          <p>Initial treatment with entecavir or tenofovir showed better clinical outcomes. The
            lowest cost-effectiveness ratio was for entecavir in HBeAg-positive patients (R$
            4,010.84/LY) and lamivudine for HBeAg-negative patients (R$ 6,205.08/LY). For
            HBeAg-negative patients, the incremental cost-effectiveness ratio of entecavir (R$
            14,101.05/LY) is below the threshold recommended by the World Health Organization.
            Sensitivity analysis showed that variation in the cost of drugs may make tenofovir a
            cost-effective alternative for both HBeAg-positive and HBeAg-negative patients.</p>
        </sec>
        <sec>
          <title>CONCLUSIONS</title>
          <p>Entecavir is the recommended alternative to start treating patients with chronic
            hepatitis B in Brazil. However, if there is a reduction in the cost of tenofovir, it can
            become a cost-effective alternative.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Hepatitis B, Chronic, drug therapy</kwd>
        <kwd>Antiviral Agents, supply &amp; distribution</kwd>
        <kwd>Cost-Effectiveness Evaluation</kwd>
        <kwd>Unified Health System, economics</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>INTRODUCTION</title>
        <p>Chronic hepatitis B (CHB) is a highly prevalent disease, with an estimated 350 million
          cases worldwide. <xref ref-type="bibr" rid="B13"><sup>13</sup></xref> According to the
          Information System for Notifiable Diseases (SINAN), between 1999 and 2010 there were
          104,454 confirmed cases in Brazil. In 2009 alone there were 14,468 confirmed cases, giving
          a detection rate of 7.6 per 100,000 inhabitants. <xref ref-type="fn" rid="fn9"
              ><sup>a</sup></xref> Patients with CHB may develop progressive liver disease, which
          can result in cirrhosis and hepatocellular carcinoma. These stages of the disease are
          linked to an increased risk of morbidity and mortality, as well as involving considerable
          health care costs. <xref ref-type="bibr" rid="B21"><sup>21</sup></xref>
        </p>
        <p>CHB is caused by the hepatitis B virus (HBV) and diagnosis is confirmed if the patient
          has HBV surface antigens (HBsAg) for at least six months, as well as increased liver
          enzymes and histological findings. These patients can then be further subdivided, based on
          the presence of the “e” hepatitis B antigen (HBeAg) in the serum, either HBeAg-positive or
          HBeAg-negative. These groups differ in their natural history and response to antiviral
          treatment, with HBeAg-negative often associated with worse prognoses and response to
          treatment. <xref ref-type="bibr" rid="B25"><sup>25</sup></xref> CHB treatment aims for the
          sustained repression of HBV replication, remission from liver disease and preventing
          cirrhosis, liver failure and hepatocellular carcinoma. In HBeAg-positive patients, durable
          HBeAg seroconversion to anti-HBe is a significant marker, associated with better
          prognostics. <xref ref-type="bibr" rid="B11"><sup>11</sup></xref>
        </p>
        <p>Before 2009, in Brazil, interferon and lamivudine were the only CHB treatments covered by
          the Brazilian Unified Health System (SUS). Adefovir dipivoxil, entecavir, pegylated
          interferon and tenofovir were then included in the treatment guidelines for this disease.
          Interferon was established as the first choice for treating HBeAg-positive patients and
          tenofovir for those who were HBeAg-negative. <xref ref-type="fn" rid="fn10"
            ><sup>b</sup></xref> These six drugs were part of the Specialized Component of
          Pharmaceutical Care (SCPC) and were made available through the Ministério da Saúde
          National Policy for Pharmaceutical Care. <xref ref-type="fn" rid="fn11"
            ><sup>c</sup></xref>
        </p>
        <p>SUS spending on SCPC medications has shown an uninterrupted tendency to increase, going
          from R$ 685 million in 2000 (R$ 4.01 <italic>per capita</italic> ) to 1.41 billion in 2007
          (R$ 7.40 <italic>per capita</italic> ). <xref ref-type="bibr" rid="B2"><sup>2</sup></xref>
          <sup>,</sup>
          <xref ref-type="fn" rid="fn12"><sup>d</sup></xref> This situation means that financial
          resources aimed at health care need to be optimized.</p>
        <p>There is little evidence focusing on the use of tenofovir in Brazil. To renew or reject
          the option set in the treatment guidelines, it is important to carry out studies to better
          understand the economic impact and the public health results.</p>
        <p>This study aims to assess the cost-effectiveness of different drug therapies for adults
          with chronic hepatitis B.</p>
      </sec>
      <sec sec-type="methods">
        <title>METHODS</title>
        <p>Using the Markov model, <xref ref-type="bibr" rid="B29"><sup>29</sup></xref> and the
          TreeAge Pro Suite 2009 program (TreeAge Software, Inc), a hypothetical cohort of HBeAg
          positive and another of HBeAg negative patients were created. Both contained four groups
          using adefovir dipivoxil (ADV), entecavir (ETV), lamivudina (LAM) or tenofovir (TDF). The
          treatments considered were those appropriate for adults with chronic hepatitis B,
          treatment-naïve, had high alanine aminotransferase levels, no evidence of cirrhosis and no
          HIV co-infection. The model had a time horizon of 40 years. Life years (LY) per patient
          treated were used as a measure of effectiveness. Only direct costs were considered, and
          these were shown in Brazilian currency (R$). The analysis was from the SUS perspective, in
          other words, the results of the cost-effectiveness of the treatment were analyzed
          considering the direct costs of treatment.</p>
        <p>The model was made up of seven mutually exclusive transition states, corresponding to the
          six possible stages of the disease (CHB without complications, efficacy of treatment,
          compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma and death) and
          HBV resistance to the respective drug. For HBeAg positive patients, seroconversion
          HBeAg/Anti-HBe was considered to be the outcome of efficacy. For HBeAg negative patients,
          the outcome analyzed was undetectable serum HBV DNA (&lt; 400 copies/mL).</p>
        <p>Each cycle of the model corresponded to one year of treatment. In the first cycle, the
          population was composed of individuals with CHB, with no complications or drug resistance.
          Transition from the first to the second cycle, and so on, occurred according to the
          probabilities of transition from stage to stage. For those patients who showed viral
          resistance to the initial treatment, rescue therapy was modelled, representing the
          insertion of another nucleos(t)ide analogue to the treatment. The probabilities of
          transition were composed of data on progression of the disease ( <xref ref-type="table"
            rid="t05">Table 1</xref> ) and the efficacy of the drugs ( <xref ref-type="table"
            rid="t06">Table 2</xref> ) obtained, respectively, from randomized clinical studies and
          studies on the natural history of CHB.</p>
        <p>
          <table-wrap id="t05">
            <label>Table 1</label>
            <caption>
              <title>Annual rates of progression of the disease.</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="25%">
                <col width="50%"/>
                <col/>
                <col/>
              </colgroup>
              <tbody>
                <tr>
                  <td>Annual rate of progression</td>
                  <td align="center">Anual rate (%)</td>
                  <td align="center">Reference No.</td>
                </tr>
                <tr>
                  <td colspan="3" style="border-bottom: thin solid; border-color: #000000"/>
                </tr>
                <tr>
                  <td>CHB to CC (HBeAg-positive)</td>
                  <td align="center">6.00</td>
                  <td align="center">12, 19, 20</td>
                </tr>
                <tr>
                  <td>CHB to CC (HBeAg-negative)</td>
                  <td align="center">9.00</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td>Seroconversion HBeAg to CC</td>
                  <td align="center">1.00</td>
                  <td align="center">9</td>
                </tr>
                <tr>
                  <td>Combined response to CC</td>
                  <td align="center">1.30</td>
                  <td align="center">19</td>
                </tr>
                <tr>
                  <td>CC to DC</td>
                  <td align="center">5.00</td>
                  <td align="center">9</td>
                </tr>
                <tr>
                  <td>CHB to HCC</td>
                  <td align="center">0.50</td>
                  <td align="center">10, 31</td>
                </tr>
                <tr>
                  <td>CC to HCC</td>
                  <td align="center">2.50</td>
                  <td align="center">8, 9, 10, 31</td>
                </tr>
                <tr>
                  <td>DC to CHC</td>
                  <td align="center">2.50</td>
                  <td align="center">9</td>
                </tr>
                <tr>
                  <td>CHB to death</td>
                  <td align="center">0.35</td>
                  <td align="center">30</td>
                </tr>
                <tr>
                  <td>CC to death</td>
                  <td align="center">5.00</td>
                  <td align="center">17, 28</td>
                </tr>
                <tr>
                  <td>DC to death</td>
                  <td align="center">39.00</td>
                  <td align="center">9, 31</td>
                </tr>
                <tr>
                  <td>HCC to death (HBeAg-positive)</td>
                  <td align="center">56.00</td>
                  <td align="center">31</td>
                </tr>
                <tr>
                  <td>HCC to death (HBeAg-negative)</td>
                  <td align="center">37.20</td>
                  <td align="center">27</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <p>CC: compensated cirrhosis; DC: decompensated cirrhosis. HCC: hepatocellular
                carcinoma. CHB: chronic hepatitis B</p>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p>
          <table-wrap id="t06">
            <label>Table 2</label>
            <caption>
              <title>Annual probabilities associated with the treatments used in the model.</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="20%">
                <col width="20%"/>
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <tbody>
                <tr>
                  <td rowspan="3">Treatment</td>
                  <td colspan="2" align="center">HBeAg-positive</td>
                  <td colspan="2" align="center">HBeAg-negative</td>
                </tr>
                <tr>
                  <td colspan="4" style="border-bottom: thin solid; border-color: #000000"/>
                </tr>
                <tr>
                  <td align="center">Probability (%)</td>
                  <td align="center">Reference No.</td>
                  <td align="center">Probability (%)</td>
                  <td align="center">Reference No.</td>
                </tr>
                <tr>
                  <td colspan="5" style="border-bottom: thin solid; border-color: #000000"/>
                </tr>
                <tr>
                  <td>Adefovir</td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td> Response, year 1</td>
                  <td align="center">12</td>
                  <td align="center">22</td>
                  <td align="center">51</td>
                  <td align="center">14</td>
                </tr>
                <tr>
                  <td> Response, year 2-4</td>
                  <td align="center">13</td>
                  <td>Assumed to be equal for all</td>
                  <td align="center">15</td>
                  <td align="center">14</td>
                </tr>
                <tr>
                  <td> Resistance, year 1</td>
                  <td align="center"> </td>
                  <td align="center">11</td>
                  <td align="center"> </td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 2</td>
                  <td align="center">3</td>
                  <td align="center">11</td>
                  <td align="center">3</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 3</td>
                  <td align="center">11</td>
                  <td align="center">11</td>
                  <td align="center">11</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 4</td>
                  <td align="center">18</td>
                  <td align="center">11</td>
                  <td align="center">18</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 5</td>
                  <td align="center">29</td>
                  <td align="center">11</td>
                  <td align="center">29</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td>Entecavir</td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td> Response, year 1</td>
                  <td align="center">21</td>
                  <td align="center">4</td>
                  <td align="center">90</td>
                  <td align="center">16</td>
                </tr>
                <tr>
                  <td> Response, year 2-4</td>
                  <td align="center">13</td>
                  <td>Assumed to be equal for all</td>
                  <td align="center">42</td>
                  <td align="center">16</td>
                </tr>
                <tr>
                  <td> Resistance, year 1</td>
                  <td align="center">0.2</td>
                  <td align="center">11</td>
                  <td align="center">0.2</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 2</td>
                  <td align="center">0.5</td>
                  <td align="center">11</td>
                  <td align="center">0.5</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 3</td>
                  <td align="center">1.2</td>
                  <td align="center">11</td>
                  <td align="center">1.2</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 4</td>
                  <td align="center">1.2</td>
                  <td align="center">11</td>
                  <td align="center">1.2</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 5</td>
                  <td align="center">1.2</td>
                  <td align="center">11</td>
                  <td align="center">1.2</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td>Lamivudine</td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td> Response, year 1</td>
                  <td align="center">19</td>
                  <td align="center">18</td>
                  <td align="center">73</td>
                  <td align="center">16</td>
                </tr>
                <tr>
                  <td> Response, year 2-4</td>
                  <td align="center">13</td>
                  <td>Assumed to be equal for all</td>
                  <td align="center">29</td>
                  <td align="center">16</td>
                </tr>
                <tr>
                  <td> Resistance, year 1</td>
                  <td align="center">24</td>
                  <td align="center">11</td>
                  <td align="center">24</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 2</td>
                  <td align="center">38</td>
                  <td align="center">11</td>
                  <td align="center">38</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 3</td>
                  <td align="center">49</td>
                  <td align="center">11</td>
                  <td align="center">49</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 4</td>
                  <td align="center">67</td>
                  <td align="center">11</td>
                  <td align="center">67</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 5</td>
                  <td align="center">70</td>
                  <td align="center">11</td>
                  <td align="center">70</td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td>Tenofovir</td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td> Response, year 1</td>
                  <td align="center">21</td>
                  <td align="center">24</td>
                  <td align="center">93</td>
                  <td align="center">24</td>
                </tr>
                <tr>
                  <td> Response, year 2-4</td>
                  <td align="center">13</td>
                  <td>Assumed to be equal for all</td>
                  <td align="center">42</td>
                  <td align="center">Assumed to be equal to entecavir</td>
                </tr>
                <tr>
                  <td> Resistance, year 1</td>
                  <td align="center"> </td>
                  <td align="center">11</td>
                  <td align="center"> </td>
                  <td align="center">11</td>
                </tr>
                <tr>
                  <td> Resistance, year 2</td>
                  <td align="center"> </td>
                  <td>Assumed to be equal for all</td>
                  <td align="center"> </td>
                  <td align="center">Assumed to be equal to year 1</td>
                </tr>
                <tr>
                  <td> Resistance, year 3</td>
                  <td align="center"> </td>
                  <td>Assumed to be equal for all</td>
                  <td align="center"> </td>
                  <td align="center">Assumed to be equal to year 1</td>
                </tr>
                <tr>
                  <td> Resistance, year 4</td>
                  <td align="center"> </td>
                  <td>Assumed to be equal for all</td>
                  <td align="center"> </td>
                  <td align="center">Assumed to be equal to year 1</td>
                </tr>
                <tr>
                  <td> Resistance, year 5</td>
                  <td align="center"> </td>
                  <td>Assumed to be equal for all</td>
                  <td align="center"> </td>
                  <td align="center">Assumed to be equal to year 1</td>
                </tr>
                <tr>
                  <td>Response durability</td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td> Inicial treatment</td>
                  <td align="center">80</td>
                  <td>Assumed to be equal for all</td>
                  <td align="center">10</td>
                  <td align="center">15, 16, 23</td>
                </tr>
                <tr>
                  <td>Rescue therapy</td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td> Response, year 2</td>
                  <td align="center">8</td>
                  <td align="center">26</td>
                  <td align="center">52</td>
                  <td align="center">5</td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
        </p>
        <p>Literature on the natural history of the disease and the efficacy and effectiveness of
          treatment is scarce. The drugs examined in this economic assessment were recently approved
          by the regulatory body. Thus, studies were selected arbitrarily, based on economic
          assessments, clinical protocols (such as EASL and AASLD) and published clinical
          trials.</p>
        <p>The modeling was carried out based on the following assumptions: patients who did not
          respond to treatment continued to receive the drug for the entire period of the cohort if
          no resistance developed; rescue therapy was given to patients who developed resistance to
          the initial treatments; resistance to rescue therapy was not included; patients at
          different stages of the disease followed the natural history of Chronic hepatitis B.</p>
        <p>The monetary values of the drug treatments in the study were determined by the Drug
          Market Regulation Chamber – CMED for 2011, considering factory prices without tax, with
          the coefficient of price adjustment of 24.38% already discounted. <xref ref-type="fn"
            rid="fn13"><sup>e</sup></xref>
        </p>
        <p>Annual spending per patient, according to the stages of the disease, were obtained from a
          2005 study evaluating the direct costs of CHB in Brazil. <xref ref-type="bibr" rid="B3"
              ><sup>3</sup></xref> The values were corrected sing the National Consumer Price Index
          (IPCA) for 2011. The costs included medical fees, laboratory tests, diagnostic and
          therapeutic procedures, hospitalizations and spending on non-anti-viral medicines. The
          estimates values were taken primarily from SUS payment tables.</p>
        <p>When conducting economic assessments of health care technology, it is recommended to use
          a discount rate on the cost and the effectiveness. Bearing in mind that there is often a
          time lag between investment in health care service resources and the associated health
          care benefit, an arbitrary rate of 5%, recommended by the Ministry of Health when the time
          period under analysis lasts for more than a year, was used for costs and effectiveness.
            <xref ref-type="fn" rid="fn14"><sup>f</sup></xref> Analyses were also carried out using
          discount rates of 0% and 10% in order to assess to what extent the arbitrary selection of
          a discount rate affected the study’s conclusions. <xref ref-type="fn" rid="fn15"
              ><sup>g</sup></xref>
        </p>
        <p>At the end of the hypothetical cohort, data on the patients’ mean life expectancy and the
          proportion of patients at each stage of the disease was obtained for each group. Means for
          cost and effectiveness were calculated according to the intervention. For each
          intervention, the cost-effectiveness ratio (CER) which determined the mean spending for
          each LY was calculated. To compare between the alternatives, the incremental
          cost-effectiveness ratio (ICER) was calculated, which is the difference between the mean
          cost of two alternative treatments and the respective LY differences. The ICER represents
          the increment in financial resources necessary to obtain an addition LY in relation to a
          lower CER alternative. An intervention was deemed to be cost-effective if the value of the
          ICER was below R$ 57,048.00, <xref ref-type="fn" rid="fn12"><sup>d</sup></xref> equivalent
          to triple the <italic>per capita</italic> Gross Domestic Product (GDP) in Brazil in 2011,
          adapted according to World Health Organization (WHO) guidelines. <xref ref-type="fn"
            rid="fn16"><sup>h</sup></xref>
        </p>
        <p>Univariate sensitivity analysis was carried out to assess the uncertainties of the model
          and assumed values due to the scarcity of data in the literature. To this end, the
          probabilities of transition and the costs varied between 10% less and 10% more.</p>
      </sec>
      <sec sec-type="results">
        <title>RESULTS</title>
        <p>At the end of the cohort, treatments which began with ETV and TDF had higher proportions
          of patients with the efficacy outcome. Respectively, 44.0% and 44.3% of the HBeAg-positive
          patients attained HBeAg seroconversion. For the HBeAg-negative patients, 17.7% of patients
          who started treatment with ETV and 18.3% of those who were initially treated with TDF had
          undetectable levels of HBV DNA ( <xref ref-type="table" rid="t07">Table 3</xref> ).</p>
        <p>
          <table-wrap id="t07">
            <label>Table 3</label>
            <caption>
              <title>Proportions of patients at each stage of the disease at the end of the cohort,
                by treatment.</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="10%">
                <col width="30%"/>
                <col/>
                <col/>
                <col/>
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <tbody>
                <tr>
                  <td rowspan="3">Treatment</td>
                  <td colspan="7" align="center">Proportion</td>
                </tr>
                <tr>
                  <td colspan="7" style="border-bottom: thin solid; border-color: #000000"/>
                </tr>
                <tr>
                  <td>Response<sup>a</sup></td>
                  <td>No change</td>
                  <td>Resistence</td>
                  <td align="center">CC</td>
                  <td align="center">DC</td>
                  <td align="center">HCC</td>
                  <td align="center">Death</td>
                </tr>
                <tr>
                  <td colspan="8" style="border-bottom: thin solid; border-color: #000000"/>
                </tr>
                <tr>
                  <td>HBeAg-positive</td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td>  ADV</td>
                  <td align="center">0.314</td>
                  <td align="center">&lt; 0.000</td>
                  <td align="center">0.023</td>
                  <td align="center">0.050</td>
                  <td align="center">0.007</td>
                  <td align="center">0.003</td>
                  <td align="center">0.604</td>
                </tr>
                <tr>
                  <td>  ETV</td>
                  <td align="center">0.440</td>
                  <td align="center">&lt; 0.000</td>
                  <td align="center">0.001</td>
                  <td align="center">0.043</td>
                  <td align="center">0.005</td>
                  <td align="center">0.002</td>
                  <td align="center">0.508</td>
                </tr>
                <tr>
                  <td>  LAM</td>
                  <td align="center">0.240</td>
                  <td align="center">&lt; 0.000</td>
                  <td align="center">0.034</td>
                  <td align="center">0.052</td>
                  <td align="center">0.007</td>
                  <td align="center">0.003</td>
                  <td align="center">0.663</td>
                </tr>
                <tr>
                  <td>  TDF</td>
                  <td align="center">0.443</td>
                  <td align="center">&lt; 0.000</td>
                  <td align="center">0.000</td>
                  <td align="center">0.043</td>
                  <td align="center">0.005</td>
                  <td align="center">0.002</td>
                  <td align="center">0.506</td>
                </tr>
                <tr>
                  <td>HBeAg-negative</td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td>  ADV</td>
                  <td align="center">0.094</td>
                  <td align="center">&lt; 0.000</td>
                  <td align="center">0.012</td>
                  <td align="center">0.037</td>
                  <td align="center">0.005</td>
                  <td align="center">0.004</td>
                  <td align="center">0.847</td>
                </tr>
                <tr>
                  <td>  ETV</td>
                  <td align="center">0.180</td>
                  <td align="center">0.006</td>
                  <td align="center">&lt; 0.000</td>
                  <td align="center">0.036</td>
                  <td align="center">0.005</td>
                  <td align="center">0.004</td>
                  <td align="center">0.768</td>
                </tr>
                <tr>
                  <td>  LAM</td>
                  <td align="center">0.110</td>
                  <td align="center">&lt; 0.000</td>
                  <td align="center">0.013</td>
                  <td align="center">0.037</td>
                  <td align="center">0.005</td>
                  <td align="center">0.004</td>
                  <td align="center">0.831</td>
                </tr>
                <tr>
                  <td>  TDF</td>
                  <td align="center">0.183</td>
                  <td align="center">0.007</td>
                  <td align="center">0.000</td>
                  <td align="center">0.036</td>
                  <td align="center">0.005</td>
                  <td align="center">0.003</td>
                  <td align="center">0.766</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <p>ADV: adefovir; CC: compensated cirrhosis; CD: decompensated cirrhosis, HCC:
                hepatocellular carcinoma; ETV: entecavir; LAM: lamivudine; TDF: tenofovir</p>
              <p><sup>a</sup>In HBeAg-positiv patients, response was defined as seroconversion
                HBeAg. In HBeAg-negative patients, response was defined as undetectable levels of
                hepatitis B virus DNA.</p>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p>These treatments also offered more protection in terms of complications of the disease.
          For the group who started treatment with ETV, 44.1% of HBeAg-positive and 18.2% of
          HBeAg-negative patients did not develop CC, DC or HC, die or develop viral resistance to
          treatment. In the group initially treated with TDF, 44.4% of HBeAg-positive and 19.0% of
          HBeAg-negative patients did not develop these complications.</p>
        <p>Treatment with ADV resulted in higher costs and worse results. This alternative was,
          therefore, dominated by the other strategies. When a 5% discount rate for the costs and
          effects is considered, treatment with LAM was also dominated by ETV and TDF for
          HBeAg-positive patients. In these patients, a lower CER was observed for ETV (R$
          4,010.84/LY). The ICER for TDF, compared with ETV (R$ 162,735.04/LY) was more than treble
          per capita GDP in Brazil. For HBeAg-negative patients, treatment with LAM gave the lowest
          CER (R$ 6,205.08/LY), followed by ETV (R$ 6,532.04/LY) and TDF (R$ 6,651.64/LY). The ICER
          for ETV compared to that of LAM (R$ 18,065.14/LY) was lower than per capita GDP in Brazil.
          Compared with ETV, TDF had a CER of R$ 71,956.13 per LY, which is higher than the limit
          suggested by the WHO ( <xref ref-type="table" rid="t08">Table 4</xref> ).</p>
        <p>
          <table-wrap id="t08">
            <label>Table 4</label>
            <caption>
              <title>Results for cost-effectiveness with a discount rate of 5% on the costs and
                effects.</title>
            </caption>
            <table frame="hsides" rules="groups">
              <colgroup width="14%">
                <col/>
                <col/>
                <col/>
                <col/>
                <col/>
                <col/>
                <col/>
              </colgroup>
              <tbody>
                <tr>
                  <td>Treatment<sup>a</sup></td>
                  <td align="center">Cost (R$)<sup>b</sup></td>
                  <td align="center">Incremental cost (R$)<sup>c</sup></td>
                  <td align="center">Effectiveness (LY)</td>
                  <td align="center">Incremental effectiveness (LY)<sup>c</sup></td>
                  <td align="center">CER (R$/LY)</td>
                  <td align="center">ICER (R$/LY)<sup>c</sup></td>
                </tr>
                <tr>
                  <td colspan="7" style="border-bottom: thin solid; border-color: #000000"/>
                </tr>
                <tr>
                  <td>HBeAg-positive</td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td> ETV</td>
                  <td align="center">57,401.84</td>
                  <td> </td>
                  <td align="center">14.31</td>
                  <td> </td>
                  <td align="center">4,010.84</td>
                  <td> </td>
                </tr>
                <tr>
                  <td> TDF</td>
                  <td align="center">59,307.01</td>
                  <td align="center">1,905.17</td>
                  <td align="center">14.32</td>
                  <td align="center">0.01</td>
                  <td align="center">4,140.57</td>
                  <td align="center">162,735.04</td>
                </tr>
                <tr>
                  <td> LAM</td>
                  <td align="center">66,937.69</td>
                  <td align="center">7,630.69</td>
                  <td align="center">13.59</td>
                  <td align="center">-0.74</td>
                  <td align="center">4,927.27</td>
                  <td align="center">(Dominated)</td>
                </tr>
                <tr>
                  <td> ADV</td>
                  <td align="center">80,484.43</td>
                  <td align="center">21,177.42</td>
                  <td align="center">13.85</td>
                  <td align="center">-0.47</td>
                  <td align="center">5,811.16</td>
                  <td align="center">(Dominated)</td>
                </tr>
                <tr>
                  <td>HBeAg-negative</td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                  <td> </td>
                </tr>
                <tr>
                  <td> LAM</td>
                  <td align="center">74,900.36</td>
                  <td> </td>
                  <td align="center">12.07</td>
                  <td> </td>
                  <td align="center">6,205.08</td>
                  <td> </td>
                </tr>
                <tr>
                  <td> ETV</td>
                  <td align="center">81,082.47</td>
                  <td align="center">4,915.76</td>
                  <td align="center">12.42</td>
                  <td align="center">0.35</td>
                  <td align="center">6,426.71</td>
                  <td align="center">14,101.05</td>
                </tr>
                <tr>
                  <td> TDF</td>
                  <td align="center">82,718.16</td>
                  <td align="center">2,902.05</td>
                  <td align="center">12.44</td>
                  <td align="center">0.02</td>
                  <td align="center">6,651.64</td>
                  <td align="center">177,658.84</td>
                </tr>
                <tr>
                  <td> ADV</td>
                  <td align="center">103,608.92</td>
                  <td align="center">20,890.76</td>
                  <td align="center">11.92</td>
                  <td align="center">-0.52</td>
                  <td align="center">8,693.69</td>
                  <td align="center">(Dominated)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <p>ADV: adefovir; LY: Life years gained; ETV: entecavir; LAM: lamivudine; CER:
                cost-effectiveness ratio; ICER: incremental cost-effectiveness ratio</p>
              <p><sup>a</sup>Treatments listed in order of increasing cost, according to the disease
                subtype.</p>
              <p><sup>b</sup>Exchange rate as of 29/12/2011: US$ 1.00 = R$ 1.87.</p>
              <p><sup>c</sup>Values regarding the non-dominated drug with the closest cost.</p>
            </table-wrap-foot>
          </table-wrap>
        </p>
        <p>When the situation is analyzed without applying discount rates, the CER of ETV (R$
          3,141.17/LY) for HBeAg-positive patients was lower than that of TDF (R$ 3,219.87/LY). The
          ICER for TDF in relation to ETV was R$ 52,966.58 per LY. For HBeAg-negative patients,
          treatment with LAM was dominated by ETV and TDF. The CER for ETV (R$ 5,894.36/LY) was
          lower than that of TDF (R$ 6,079.00/LY). The ICER for TDF compared to ETV was R$ 81,081.06
          per LY.</p>
        <p>When a discount rate of 10% was applied to costs and effects, the CER for ETV and TDF was
          R$ 4,665.08/LY and R$ 4,838.21/LY respectively for HBeAg-positive patients. The ICER for
          TDF compared to ETV was R$ 433,119.83 per LY. For HBeAg-negative patients, the lowest CER
          was for LAM (R$ 5,999.10/LY), followed by ETV (R$ 6,701.40/LY) and TDF (R$ 6,953.76/LY).
          The ICER for ETV compared to LAM was R$ 55,668.84 per LY. Considering TDF compared to ETV,
          the ICER was R$ 354,997.16 per LY.</p>
        <p>According to sensitivity analysis, for HBeAg-positive patients, the variation of
          antiviral costs over the period of the cohort may make ICER lower than the threshold
          suggested by the WHO. For HBeAg-negative patients, the variation in the cost of
          antivirals, in the first year and in subsequent years, the ICER for TDF compared to ETV
          may also be less than triple Brazilian per capita GDP. Alteration in the variables
          considered in the model for HBeAg-negative patients did not make the ICER for ETV,
          compared to LAM, higher than three times Brazilian per capita GDP ( <xref ref-type="fig"
            rid="f02">Figure</xref> ).</p>
        <p>
          <fig id="f02">
            <label>Figure</label>
            <caption>
              <title>Univariate sensitivity analysis between non-dominated treatment strategies. A)
                TDF <italic>versus</italic> ETV, HBeAg-positive; B) ETV <italic>versus</italic> LAM,
                HBeAg-negative; C) TDF <italic>versus</italic> LAM, HBeAg-negative; D) TDF
                  <italic>versus</italic> ETV, HBeAg-negative.</title>
            </caption>
            <graphic xlink:href="0034-8910-rsp-47-04-0769-gf01-en"/>
          </fig>
        </p>
      </sec>
      <sec sec-type="discussion">
        <title>DISCUSSION</title>
        <p>Considering the clinical evidence used and the cost defined by the CMED for nucleos(t)ide
          analogues, the most cost-effective alternative for HBeAg-positive patients was starting
          treatment with ETV and it is cost-effective, compared to LAM, for HBeAg-negative
          patients.</p>
        <p>In HBeAg-positive patients, starting treatment with LAM produced higher costs and lower
          values for LY compared to ETV and TDF, characterizing it as a dominated alternative. For
          both subtypes of the disease, starting treatment with ADV was also dominated by ETV and
          TDF. These dominated options are not recommended for starting treatment.</p>
        <p>The CER for ETV was lower compared to the other treatments for HBeAg-positive patients,
          with a cost of R$ 4,010.84 each LY. Treatment with TDF would necessitate an incremental
          investment of R$ 162,735.04 per additional LY. Although this value is above the threshold
          set by the WHO, sensitivity analysis indicates that this situation may be reversed if the
          cost of the drug decreases, or if the cost of ETV increases. If these variations in cost
          are taken into account, starting treatment with TDF may also be considered the most
          cost-effective alternative.</p>
        <p>In HBeAg-negative patients, the lowest CER was for treatment started with LAM. In order
          to reach one more LY with ETV compared to LAM, an incremental investment of R$ 18,065.14
          is necessary. This value is lower than the threshold suggested by the WHO of three times
          national <italic>per capita</italic> GDP, which means ETV can be characterized as a
          cost-effective alternative. With regards treatment started with TDF, incremental
          investments of R$ 21,421.93 and R$ 71,956.13 for each LY would be necessary for treatment
          with LAM or ETV, respectively. Sensitivity analysis shows that, if variations in the costs
          of ETV and TDF are taken into account, this may also be a cost-effective alternative.</p>
        <p>As it has a slight advantage over ETV, the model indicates that starting treatment with
          TDF gives better clinical results compared with the other treatments. With this treatment,
          there is a greater probability of obtaining efficacy as the outcome and a lower chance of
          progression to HBC complications.</p>
        <p>Economic models are simplifications of reality. The multifaceted complexity of treating a
          disease cannot be completely covered using this approach. Economic analyses support the
          decisions of those responsible for coordinating health care programs and services. These
          decisions should take into account factors and premises considered in the model, as well
          as others which are not modelled. Thus, some limitations to this study can be identified,
          such as obtaining costs from secondary sources, using data for efficacy and effectiveness
          obtained from studies of international populations, the arbitrary selection of studies to
          create the model and the extrapolation of clinical data, resistance rates and rescue
          therapy.</p>
        <p>The perspective used for the cost-effectiveness analysis was that of the Brazilian
          Unified Health System. However, the data used were not obtained from national databases
          such as the Outpatient Information System – Sistema de Informações Ambulatoriais. Another
          limitation of this study concerns the data for efficacy and progression of the disease,
          which were taken from studies which did not deal with Brazilian patients. These data were
          used due to the lack of clinical studies on this disease in a national context. There are
          also few prospective studies for CHB, due to the long follow up period. Thus, the clinical
          data on response to treatment were extrapolated to the end of the hypothetical cohort.</p>
        <p>Estimates of the effectiveness of rescue therapies after one year are few. Therefore,
          evaluating the data obtained for substituting a therapy due to viral resistance should be
          approached with caution.</p>
        <p>Cost-utility analysis from the perspective of health care services in other countries
          highlighted TDF as the most cost-effective option compared to ETV and LAM. A study from
          the Spanish perspective indicated TDF as responsible for higher life expectancy and lower
          costs compared to the other treatments. <xref ref-type="bibr" rid="B1"><sup>1</sup></xref>
          A study carried out from the perspective of the Italian national health care system
          concluded that TDF was the most cost-effective alternative. <xref ref-type="bibr" rid="B6"
              ><sup>6</sup></xref> In both of these studies, the annual cost of this drug was lower
          than other nucleos(t)ide analogues, ranging between 66.6% and 73.2% of the annual cost for
          ETV. In Brazil, according to the values set by the CMED, the annual cost of TDF is 107.9%
          that of ETV. In concordance with the results of this study, cost-effectiveness analysis
          comparing ETV and LAM from the perspective of the Brazilian Unified Health System
          concluded that treatment with ETV is the most cost-effective treatment. <xref
            ref-type="bibr" rid="B7"><sup>7</sup></xref>
        </p>
        <p>Sensitivity analysis makes it possible to assess the uncertainties, with a variation of
          10% for each value used, allowing the robustness of the study’s results in relation to the
          assumptions adopted to be considered. It was possible to define that the ICER is more
          sensitive to variations in the costs of the drugs. When the proposed variation is
          considered, situations in which ETV and TDF may be deemed to be cost-effective appear,
          with ICER below the threshold recommended for incorporating technologies in Brazil.</p>
        <p>Bearing in mind the scientific output currently available, the assessment emphasizes
          incorporating and prioritizing ETV and TDF as nucleos(t)ide analogues in clinical protocol
          and treatment guideline for Chronic hepatitis B. There are some initiatives which may be
          important in reducing the prices of these drugs. One of these is incentivizing the use of
          official laboratories, rather than private, in producing low cost drugs. This would make
          treatment with TDF, which had the best clinical results, also produce better
          cost-effectiveness results compared with ETV. This action would lead to better treatment
          for the population affected by CHB.</p>
        <p>Of the antivirals considered, ETV and TDF showed the best clinical results. For
          HBeAg-positive patients, they are the most cost-effective alternatives. For HBeAg-negative
          patients, they were reasonably cost-effective for use in Brazil. Thus, taking into account
          the perspective of the SUS and the data in the model, using ETV and TDF are the
          recommended options for starting CHB treatment in adult patients with no HIV co-infection.
          In order to reinforce these findings, more clinical studies – principally in Brazil – are
          necessary, as are budget impact studies.</p>
      </sec>
    </body>
    <back>
      <app-group>
        <p>HIGHLIGHTS</p>
        <p>Considering the limited health care resources available, the increase in life expectancy,
          the increased mean age of the population, the higher prevalence of chronic compared with
          non-chronic health problems, and the growing appearance of pharmaceutical innovations,
          using pharma-economic knowledge and methods has become essential. Within the Brazilian
          Unified Health System (SUS), spending on medication from the Specialized Component of
          Pharmaceutical Care has grown without interruption, going from R$ 685 million in 2000 (R$
          4.01 <italic>per capita</italic> ) to R$ 1.41 billion in 2007 (R$ 7.40 <italic>per
            capita</italic> ). This situation calls for the rationalization and optimization of
          financial resources dedicated to pharmaceutical care.</p>
        <p>Patients with chronic hepatitis B in Brazil have been treated with antivirals without
          pharma-economic studies being carried out in this context. This article uses a
          hypothetical cohort of patients with chronic hepatitis, both with and without positive
          HBeAg, in order to analyze the cost-effectiveness of the different drug therapies
          available. The outcome used was the life years gained in each of the alternatives.</p>
        <p>At current prices, the most cost-effective treatments were Entecavir for HBeAg positive
          patients and Lamivudine for the HBeAg negative ones.</p>
        <p>Profa. Rita de Cássia Barradas Barata</p>
        <p>Scientific Editor</p>
      </app-group>
      <fn-group>
        <fn id="fn9">
          <label>a</label>
          <p>Ministério da Saúde. Bol Epidemiol Hepatites Virais. 2011;2(1):5-76. [cited 2011 Sept].
            Available from:
            http://www.aids.gov.br/publicacao/2011/boletim_epidemiologico_hepatites_virais_2011</p>
        </fn>
        <fn id="fn10">
          <label>b</label>
          <p>Ministério da Saúde. Portaria nº 2.561, de 28 de outubro de 2009. Aprova Protocolo
            Clínico e Diretrizes Terapêuticas - Hepatite Viral Crônica B e Coinfecções.
              <italic>Diario Oficial da Uniao</italic> , Brasília, DF, 3 nov. 2009. Seção 1,
            p.59-71.  </p>
        </fn>
        <fn id="fn11">
          <label>c</label>
          <p>Ministério da Saúde. Portaria nº 2.981, de 26 de novembro de 2009. Aprova o Componente
            Especializado da Assistência Farmacêutica. <italic>Diario Oficial da Uniao</italic> ,
            Brasília, DF, 30 nov. 2009. Seção 1, p.725-771</p>
        </fn>
        <fn id="fn12">
          <label>d</label>
          <p>The exchange rate as of 29/12/2011 (US$ 1.00 = R$ 1.87) was used for the monetary
            values in this study.</p>
        </fn>
        <fn id="fn13">
          <label>e</label>
          <p>Câmara de Regulação do Mercado de Medicamentos. Resolução nº 3, de 2 de março de 2011.
              <italic>Diario Oficial da Uniao</italic> , Brasília, DF, 9 mar. 2011. Seção 1, p.3</p>
        </fn>
        <fn id="fn14">
          <label>f</label>
          <p>Abbot T. Custo em saúde, qualidade e desfechos. São Paulo: ISPOR Brasil; 2009.</p>
        </fn>
        <fn id="fn15">
          <label>g</label>
          <p>Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos,
            Departamento de Ciência e Tecnologia. Diretrizes metodológicas: estudos de avaliação
            econômica de tecnologias em saúde. Brasília (DF); 2009. (Série A. Normas e Manuais
            Técnicos)</p>
        </fn>
        <fn id="fn16">
          <label>h</label>
          <p>World Health Organization. Cost-effectiveness thresholds. Geneva; 2005 [cited 2011 Nov
            3]. Available from: http://www.who.int/choice/costs/CER_thresholds/en/index.html</p>
        </fn>
        <fn id="fn17" fn-type="supplementary-material">
          <p>The article is based on the dissertation of Oliveira G.L.A., entitled: “Avaliação
            econômica de tenofovir para o tratamento da hepatite B crônica sob a perspectiva do
            sistema público de saúde brasileiro <italic>”</italic> , presented to the Faculty of
            Medicine of the <italic>Universidade Federal de Minas Gerais</italic> , in 2012.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
